Leucovorin
Regulatory milestones approvals, filings & regulatory actions · 5 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | WELLCOVORIN | — | 2026-03-09 | fda.gov ↗ |
| Label expansions (3) | US (FDA) | LEUCOVORIN CALCIUM | — | 1987-01-30 – 1991-12-12 | fda.gov ↗ |
| Approved | US (FDA) | LEUCOVORIN CALCIUM | — | 1952-06-20 | fda.gov ↗ |
Trials 772 · started per year
Also used as a comparator or background therapy in 1,110 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 08 trials | ||||||
| Phase 0 | NCT07328087 Background | Feb 2026 → Dec 2030 expected | colorectal cancer | Biogenea Pharmaceuticals Ltd. | Recruiting | No outcome recorded |
| Phase 0 | NCT06011772 Background | Dec 2023 → Feb 2026 overdue | colorectal cancer | Roswell Park Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 0 | NCT05590117 Comparator | Oct 2022 → Oct 2023 | colorectal cancer, mucositis, peripheral neuropathy | Tanta University | Unknown | No outcome recorded |
| Phase 0 | NCT05108428 Background | Dec 2021 → Oct 2023 overdue | rectum adenocarcinoma | H. Lee Moffitt Cancer Center and Research Institute | Active not recruiting | No outcome recorded |
| Phase 0 | NCT03684980 Background | Nov 2018 → Nov 2027 expected | central nervous system non-hodgkin lymphoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 0 | NCT03515941 Background | Jun 2018 → Mar 2020 | digestive system cancer | Tannaz Armaghany | Terminated | No outcome recorded |
| Phase 0 | NCT01737671 Background | Dec 2012 → Jan 2018 | cerebral ventricle cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 0 | NCT01184885 Background | Jul 2010 → Mar 2011 | Burkitt lymphoma, acute lymphoblastic leukemia, adult T-cell leukemia/lymphoma, lymphoblastic lymphoma +1 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Completed | No outcome recorded |
| Phase 1173 trials | ||||||
| Phase 1 | NCT07700420 Background | Oct 2026 → Oct 2027 expected | esophageal cancer, gastroesophageal cancer | University of Texas Southwestern Medical Center | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07543471 Background | Jun 2026 → Jun 2027 expected | colorectal cancer | Shanghai Henlius Biotech | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07671339 Background | Jun 2026 → Jun 2028 expected | pancreatic ductal adenocarcinoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT07619313 Background | Jun 2026 → Jun 2027 expected | cholangiocarcinoma, pancreatic ductal adenocarcinoma | Jonsson Comprehensive Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07532902 Background | Apr 2026 → Apr 2029 expected | diffused pleural mesothelioma, gastroesophageal cancer, urothelial carcinoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Show all 173 trials opens the full record — a long page | ||||||
| Phase 1/2105 trials | ||||||
| Phase 1/2 | NCT07705919 Background | Sep 2026 → Dec 2027 expected | pancreatic ductal adenocarcinoma | Ohio State University Comprehensive Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07678593 Background | Sep 2026 → Nov 2027 expected | pancreatic ductal adenocarcinoma | Genfleet Therapeutics (Shanghai) Inc. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07683403 Comparator | Jun 2026 → Jun 2028 expected | colorectal cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07680569 Background | Jun 2026 → Dec 2027 expected | gastroesophageal junction adenocarcinoma | Kaohsiung Medical University Chung-Ho Memorial Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07391566 Background | Mar 2026 → Dec 2028 expected | colorectal cancer | Luye Pharma Group Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07214298 Background | Feb 2026 → Feb 2028 expected | pancreatic ductal adenocarcinoma | Roswell Park Cancer Institute | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07283367 Background | Dec 2025 → Dec 2029 expected | — | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07312422 Background | Sep 2025 → Apr 2026 overdue | malignant pancreatic neoplasm | Zhejiang Provincial People's Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06936527 Background | May 2025 → Apr 2028 expected | colorectal cancer | NovaOnco Therapeutics Co., Ltd. | Enrolling by invitation | No outcome recorded |
| Phase 1/2 | NCT07204574 Background | May → Dec 2025 overdue | — | Chang Gung Memorial Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06888648 Background | Apr 2025 → Apr 2027 expected | malignant pancreatic neoplasm | Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07056777 Background | Mar 2025 → Apr 2027 expected | digestive system cancer | Zhejiang Doer Biologics Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06771622 Background | Mar 2025 → Jan 2028 expected | — | FBD Biologics Limited | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06871527 Background | Mar 2025 → Mar 2028 expected | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Sixth Affiliated Hospital, Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06741644 Background | Feb 2025 → Jan 2027 expected | cancer | CStone Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06703177 Background | Feb 2025 → Jan 2026 overdue | cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06483555 Comparator | Feb 2025 → Aug 2027 expected | basal cell neoplasm, pancreatic adenocarcinoma | UNC Lineberger Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06730009 Comparator | Oct 2024 → Jan 2029 expected | cholangiocarcinoma, exocrine pancreatic carcinoma | Medigen Biotechnology Corporation | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06598007 Background | Sep 2024 → Jun 2027 expected | colorectal cancer, pancreatic ductal adenocarcinoma | Crossignal Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06650332 Background | Jul 2024 → Aug 2026 overdue | gastroesophageal cancer | Zhejiang Cancer Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06370754 Background | Apr 2024 → Apr 2026 overdue | malignant pancreatic neoplasm | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06385925 Background | Apr 2024 → Oct 2026 expected | cancer | Tyligand Pharmaceuticals (Suzhou) Limited | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06139211 Background | Jan 2024 → Nov 2025 overdue | neoplasm | Shanghai Junshi Bioscience Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05926206 Background | Jul 2023 → Jan 2027 | pancreatic adenocarcinoma | University of Michigan Rogel Cancer Center | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT05846867 Background | May 2023 → May 2026 overdue | colorectal cancer | Akeso | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05714553 Background | Mar 2023 → May 2025 | cancer of unknown primary site, carcinoma of esophagus, classic Hodgkin lymphoma, colorectal cancer +11 | NuCana plc | Terminated | No outcome recorded |
| Phase 1/2 | NCT05721872 Comparator | Feb → Aug 2023 | colorectal cancer | Nazarbayev University | Unknown | No outcome recorded |
| Phase 1/2 | NCT05609370 Background | Jan 2023 → May 2025 overdue | colorectal cancer | BeiGene | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05419479 Comparator | Nov 2022 → May 2026 | pancreatic adenocarcinoma, pancreatic adenosquamous carcinoma | James Cleary, MD, PhD | Suspended | No outcome recorded |
| Phase 1/2 | NCT05585320 Background | Oct 2022 → Jun 2026 overdue | cutaneous melanoma, non-small cell lung carcinoma, pancreatic adenocarcinoma | Immuneering Corporation | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05251038 Background | Sep 2022 → Jan 2023 | malignant pancreatic neoplasm | Devalingam Mahalingam | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02826837 Background | Sep 2022 → Feb 2024 | colorectal cancer | Taiwan Leader Biotech Corp. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05192889 Background | Aug 2022 → Jun 2024 overdue | acute lymphoblastic leukemia | St. Jude Children's Research Hospital | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05379595 Comparator | Jul 2022 → Apr 2027 expected | colorectal cancer | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05032183 Background | Feb 2022 → Jul 2024 | B-cell acute lymphoblastic leukemia, T-cell acute lymphoblastic leukemia | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT04821284 Background | Dec 2021 → Oct 2025 overdue | pancreatic ductal adenocarcinoma | Flemming Forsberg | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT07280377 Background | Oct 2021 → Jul 2027 expected | anal squamous cell carcinoma, pancreatic ductal adenocarcinoma | Oncolytics Biotech | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05121038 Background | Oct 2021 → Sep 2025 overdue | colon carcinoma, malignant pancreatic neoplasm | Anup Kasi | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05083481 Background | Oct 2021 → May 2026 | — | Astellas Pharma Global Development, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT05116891 Background | Sep 2021 → Jun 2023 | biliary tract cancer, colorectal cancer, non-small cell lung carcinoma | Cantargia AB | Completed | No outcome recorded |
| Phase 1/2 | NCT04431258 Background | May 2021 → Jan 2024 | malignant pancreatic neoplasm | Ability Pharmaceuticals SL | Completed | No outcome recorded |
| Phase 1/2 | NCT04752163 Background | Mar 2021 → Nov 2023 | acute lymphoblastic leukemia, acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT04689347 Background | Jan 2021 → Apr 2026 overdue | colorectal cancer | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03985891 Background | Dec 2020 → Jun 2025 | chemotherapy-induced toxicity, colonic neoplasm | Xiangya Hospital of Central South University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04421820 Background | Aug 2020 → Jun 2026 overdue | cholangiocarcinoma, colorectal cancer, gastric cancer, malignant pancreatic neoplasm | Bold Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04393298 Background | Jul 2020 → Apr 2024 | cancer | UCB Biopharma SRL | Completed | No outcome recorded |
| Phase 1/2 | NCT04396821 Background | May 2020 → May 2026 overdue | cancer of unknown primary site, gastric cancer, gastroesophageal junction adenocarcinoma, pancreatic adenocarcinoma | Suzhou Transcenta Therapeutics Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04068610 Background | Sep 2019 → Oct 2022 overdue | colorectal cancer | MedImmune LLC | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03829410 Background | Jun 2019 → Jan 2024 | colorectal cancer | Cardiff Oncology | Completed | No outcome recorded |
| Phase 1/2 | NCT03828799 Background | May 2019 → Dec 2021 | colorectal cancer | Institut du Cancer de Montpellier - Val d'Aurelle | Completed | No outcome recorded |
| Phase 1/2 | NCT03817320 Background | Feb 2019 → Dec 2023 overdue | childhood acute lymphoblastic leukemia | Therapeutic Advances in Childhood Leukemia Consortium | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03607643 Background | Jan 2019 → Jun 2020 | colon carcinoma, gallbladder cancer, glioblastoma, liver cancer +3 | Leaf Vertical Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT03618758 Background | Dec 2018 → Aug 2023 | gastric cancer, peritoneal carcinomatosis | Seoul National University Bundang Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT03699319 Background | Dec 2018 → Sep 2024 | pancreatic ductal adenocarcinoma | David Bajor, MD | Completed | No outcome recorded |
| Phase 1/2 | NCT03795311 Background | Nov 2018 → Jan 2023 overdue | colorectal cancer | Centre Georges Francois Leclerc | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03337087 Background | Nov 2018 → Mar 2021 | biliary tract cancer, colorectal carcinoma, gastroesophageal junction adenocarcinoma, pancreatic adenocarcinoma | Academic and Community Cancer Research United | Unknown | No outcome recorded |
| Phase 1/2 | NCT03586869 Background | Jul 2018 → Apr 2019 | malignant pancreatic neoplasm | ImmunityBio, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT03606928 Background | Jul 2018 → Nov 2019 | gastric cancer | Ruijin Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT03526835 Background | May 2018 → Nov 2025 overdue | colorectal cancer, esophageal cancer, gastric cancer, gastroesophageal junction adenocarcinoma +2 | Merus B.V. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03387085 Background | Mar 2018 → Sep 2020 | triple-negative breast carcinoma | ImmunityBio, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT03127124 Background | Feb 2018 → Dec 2023 | pancreatic adenocarcinoma | NantPharma, LLC | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03167177 Background | Dec 2017 → Jan 2019 | melanoma | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03254394 Comparator | Sep 2017 → Sep 2020 | chemotherapy-induced neuropathy, colorectal cancer, neuropathy, painful | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1/2 | NCT03221400 Background | Aug 2017 → Jan 2023 | anal squamous cell carcinoma, cervical squamous cell carcinoma, endometrium adenocarcinoma, gastric adenocarcinoma +5 | Tarveda Therapeutics | Unknown | No outcome recorded |
| Phase 1/2 | NCT03202758 Background | Aug 2017 → Jan 2023 | colorectal cancer | Centre Georges Francois Leclerc | Completed | No outcome recorded |
| Phase 1/2 | NCT03193190 Comparator | Jul 2017 → Feb 2025 | pancreatic adenocarcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1/2 | NCT03009058 Background | May → Aug 2017 | metastatic malignant neoplasm | Immodulon Therapeutics Ltd | Terminated | No outcome recorded |
| Phase 1/2 | NCT02785068 Background | Jul 2016 → May 2018 | colorectal cancer | Merrimack Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02730546 Background | Jun 2016 → Jul 2021 | gastric cardia adenocarcinoma, gastroesophageal junction adenocarcinoma | Mayo Clinic | Completed | No outcome recorded |
| Phase 1/2 | NCT02735239 Background | Jun 2016 → Jun 2022 | esophageal cancer | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
| Phase 1/2 | NCT02568046 Background | Mar 2016 → May 2017 | colorectal cancer | Symphogen A/S | Terminated | No outcome recorded |
| Phase 1/2 | NCT02671435 Background | Feb 2016 → Oct 2021 overdue | cancer | MedImmune LLC | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02553460 Background | Jan 2016 → May 2022 overdue | acute lymphoblastic leukemia | St. Jude Children's Research Hospital | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02620865 Background | Dec 2015 → Jun 2021 | pancreatic adenocarcinoma | Barbara Ann Karmanos Cancer Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT02344810 Background | Mar 2015 | diffuse gastric adenocarcinoma, esophageal adenocarcinoma, gastric intestinal type adenocarcinoma, gastroesophageal junction adenocarcinoma | Eastern Cooperative Oncology Group | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02102022 Background | Nov 2014 → Feb 2020 | colorectal cancer, gastric cancer, hepatocellular carcinoma | Polaris Group | Terminated | No outcome recorded |
| Phase 1/2 | NCT01959139 Background | Jan 2014 → Apr 2019 | pancreatic adenocarcinoma | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 1/2 | NCT01987102 Background | Dec 2013 → Jan 2017 | osteosarcoma | Isofol Medical AB | Completed | No outcome recorded |
| Phase 1/2 | NCT01611857 Background | Jul 2012 → Jul 2015 | gastroesophageal cancer | SCRI Development Innovations, LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT01231399 Background | Feb 2012 → Jul 2016 | diffuse gastric adenocarcinoma, esophageal adenocarcinoma, gastric intestinal type adenocarcinoma, gastroesophageal junction adenocarcinoma | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT01490996 Comparator | Feb 2012 → May 2017 | colorectal cancer, metastatic malignant neoplasm | University of Leicester | Completed | No outcome recorded |
| Phase 1/2 | NCT01347645 Background | Sep 2011 → Jun 2015 | colon carcinoma, rectal carcinoma | Eisai Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT01489865 Background | Jan 2011 → Dec 2018 | malignant pancreatic neoplasm | Georgetown University | Completed | No outcome recorded |
| Phase 1/2 | NCT01206530 Background | Sep 2010 → Sep 2017 | adenocarcinoma, colon carcinoma, metastatic neoplasm, rectal cancer | Abramson Cancer Center at Penn Medicine | Completed | No outcome recorded |
| Phase 1/2 | NCT01047293 Background | May 2010 → Aug 2015 | colorectal cancer | University of Utah | Completed | No outcome recorded |
| Phase 1/2 | NCT01133990 Background | Mar 2010 → Feb 2011 | colorectal cancer | Eisai Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT01085331 Background | Mar 2010 → Apr 2012 | colorectal cancer | EMD Serono | Terminated | No outcome recorded |
| Phase 1/2 | NCT00954512 Background | Sep 2009 → Jun 2011 | neoplasm | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 1/2 | NCT01102686 Background | Aug 2009 → Nov 2010 | Sandhoff disease, Tay-Sachs disease | The Hospital for Sick Children | Completed | No outcome recorded |
| Phase 1/2 | NCT00932438 Background | Jun 2009 → Dec 2012 | metastasis from malignant tumor of colon | University of Louisville | Completed | No outcome recorded |
| Phase 1/2 | NCT00964080 Background | May 2009 → Oct 2012 | esophageal adenocarcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Mebiopharm Co., Ltd | Unknown | No outcome recorded |
| Phase 1/2 | NCT00778830 Background | Feb 2009 → Apr 2014 | colorectal cancer | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 1/2 | NCT00727831 Background | Jul 2008 → Jul 2011 | chemotherapy-induced toxicity, lymphoma, mucositis | University College, London | Completed | No outcome recorded |
| Phase 1/2 | NCT00625651 Background | Oct 2007 → Aug 2010 | colon carcinoma, rectal carcinoma | Amgen | Completed | No outcome recorded |
| Phase 1/2 | NCT00494221 Comparator | Jun 2007 → Oct 2009 | colorectal cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1/2 | NCT00478946 Background | Apr 2006 → Dec 2009 | colorectal cancer | Poniard Pharmaceuticals | Unknown | No outcome recorded |
| Phase 1/2 | NCT00098839 Background | Feb 2005 → Apr 2011 | childhood acute lymphoblastic leukemia | Children's Oncology Group | Completed | No outcome recorded |
| Phase 1/2 | NCT00463840 Background | Jun 2004 → Jul 2010 | malignant pancreatic neoplasm | NYU Langone Health | Terminated | No outcome recorded |
| Phase 1/2 | NCT00291785 Background | Jan 2004 → Aug 2007 | colorectal cancer | CTI BioPharma | Completed | No outcome recorded |
| Phase 1/2 | NCT00237900 Background | Jul 2003 → Feb 2004 | microinvasive gastric cancer | AstraZeneca | Terminated | No outcome recorded |
| Phase 1/2 | NCT00061945 Background | Jun 2003 → Dec 2007 | B-cell adult acute lymphocytic leukemia, B-cell childhood acute lymphoblastic leukemia, T-cell adult acute lymphocytic leukemia, T-cell childhood acute lymphocytic leukemia +1 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT00055822 Background | Oct 2002 → Oct 2004 | colorectal cancer | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 1/2 | NCT00049101 Background | Aug 2002 → Aug 2004 | colorectal cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00016133 Background | Mar 2001 → Aug 2004 | colorectal cancer | Intracel | Completed | No outcome recorded |
| Phase 1/2 | NCT00289445 Background | Sep 1999 → Mar 2006 | digestive system cancer, metastatic malignant neoplasm | University Hospital Tuebingen | Completed | No outcome recorded |
| Phase 2487 trials | ||||||
| Phase 2 | NCT07625930 Background | Jan 2027 → Apr 2029 expected | gastroesophageal adenocarcinoma | McGill University Health Centre/Research Institute of the McGill University Health Centre | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07636564 Background | Oct 2026 → Apr 2031 expected | B-cell acute lymphoblastic leukemia, T-cell acute lymphoblastic leukemia, acute leukemia of ambiguous lineage | SWOG Cancer Research Network | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06890624 Comparator | Oct 2026 → Oct 2029 expected | malignant colon neoplasm | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07059611 Background | Sep 2026 → Nov 2027 expected | esophageal adenocarcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Abramson Cancer Center at Penn Medicine | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07662031 Background | Aug 2026 → Aug 2030 expected | colorectal cancer | Washington University School of Medicine | Not yet recruiting | No outcome recorded |
| Show all 487 trials opens the full record — a long page | ||||||
| Phase 2/335 trials | ||||||
| Phase 2/3 | NCT07437287 Background | Jul 2026 → Apr 2030 expected | biliary tract cancer | UNICANCER | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07490301 Background | Apr 2026 → Jun 2031 expected | pancreatic ductal adenocarcinoma | AbbVie | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06841679 Background | Aug 2025 → Sep 2030 expected | gastroesophageal adenocarcinoma | Beijing Biostar Pharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06959693 Background | Jun 2025 → Sep 2028 expected | colorectal cancer | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06758830 Background | Jan 2025 → Dec 2029 expected | rectal cancer | National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06662877 Comparator | Nov 2024 → Sep 2029 expected | biliary tract cancer | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06079346 Comparator | May 2024 → Jun 2026 overdue | pancreatic ductal adenocarcinoma | Oncotelic Inc. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05484024 Background | Aug 2022 → Jul 2028 expected | rectal cancer | Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06509880 Comparator | Jul 2022 → Jul 2023 | — | MIPO Clinic | Completed | No outcome recorded |
| Phase 2/3 | NCT05174169 Comparator | Jul 2022 → Mar 2029 expected | malignant colon neoplasm | NRG Oncology | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05065957 Comparator | Mar 2022 → Jul 2026 overdue | biliary tract cancer | InnoPharmax Inc. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05141721 Background | Feb 2022 → Mar 2027 expected | colorectal neoplasm | Seattle Project Corporation | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT04037241 Background | Nov 2021 → Jan 2022 | malignant pancreatic neoplasm | Sorrento Therapeutics, Inc. | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT05179889 Background | Jul 2021 → Jul 2028 expected | malignant colon neoplasm | Chungnam National University Hospital | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03414983 Background | Feb 2018 → Feb 2021 | colorectal cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2/3 | NCT03280979 Background | Oct 2017 → Jul 2019 | gestational trophoblastic neoplasm | Assiut University | Unknown | No outcome recorded |
| Phase 2/3 | NCT03130790 Comparator | Aug 2017 → Dec 2018 | gastric cancer | ASLAN Pharmaceuticals | Completed | No outcome recorded |
| Phase 2/3 | NCT02581462 Background | Jun 2016 → Jul 2020 | gastric cancer, gastroesophageal junction adenocarcinoma | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Completed | No outcome recorded |
| Phase 2/3 | NCT02661971 Background | Jun 2016 → Dec 2021 | gastric cancer, gastroesophageal cancer | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Completed | No outcome recorded |
| Phase 2/3 | NCT03031444 Comparator | Jan 2016 → Dec 2020 | colorectal cancer, metastatic neoplasm | Peking University Cancer Hospital & Institute | Completed | No outcome recorded |
| Phase 2/3 | NCT01404156 Comparator | Sep 2015 → Aug 2023 | esophageal adenocarcinoma, gastroesophageal junction adenocarcinoma | Dr. Gordon Buduhan | Completed | No outcome recorded |
| Phase 2/3 | NCT02606539 Comparator | Sep 2015 → Jun 2017 | gestational trophoblastic neoplasm | Maher elesawi kamel elesawi | Unknown | No outcome recorded |
| Phase 2/3 | NCT02527772 Comparator | Sep 2015 → Sep 2017 | hepatocellular carcinoma | Guangxi Medical University | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT02534337 Comparator | Sep 2015 → Sep 2017 | hepatocellular carcinoma | Guangxi Medical University | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT02590367 Background | Aug 2015 → Oct 2017 | peripheral neuropathy | Jiangsu Province Hospital of Traditional Chinese Medicine | Unknown | No outcome recorded |
| Phase 2/3 | NCT02415699 Background | Aug 2015 → Jul 2017 | colorectal cancer | Sixth Affiliated Hospital, Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2/3 | NCT02510118 Background | Jun 2015 → Jun 2016 | colon carcinoma | Nanjing NingQi Medicine Science and Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 2/3 | NCT02066220 Background | Jun 2014 → Dec 2026 expected | brain cancer | University Medical Center Hamburg-Eppendorf | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT01646554 Background | Dec 2012 → Dec 2015 | metastasis from malignant tumor of colon | European Organisation for Research and Treatment of Cancer - EORTC | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT01523431 Background | Mar 2012 → Nov 2015 | colorectal cancer | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | Completed | No outcome recorded |
| Phase 2/3 | NCT01046825 Background | Sep 2010 → Aug 2023 overdue | neoplasm of mature B-cells | St. Jude Children's Research Hospital | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT00952029 Background | Mar 2010 → Dec 2015 | colorectal cancer | Federation Francophone de Cancerologie Digestive | Completed | No outcome recorded |
| Phase 2/3 | NCT00720109 Background | Jul 2008 → Dec 2014 | B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2), acute lymphoblastic leukemia | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2/3 | NCT00384176 Background | Aug 2006 → Nov 2009 | colorectal cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 2/3 | NCT00785421 Comparator | Apr 2004 → Jan 2009 | pancreatic adenocarcinoma | CONKO-Studiengruppe | Completed | No outcome recorded |
| Phase 3247 trials | ||||||
| Phase 3 | NCT07271355 Background | Jul 2026 → Feb 2031 expected | appendix carcinoma, peritoneal carcinomatosis | City of Hope Medical Center | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07702032 Background | Jul 2026 → Jul 2029 expected | colorectal cancer | Genmab | Recruiting | No outcome recorded |
| Phase 3 | NCT07595913 Comparator | Jul 2026 → Jun 2028 expected | neuroendocrine carcinoma | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07673887 Background | Jun 2026 → Feb 2031 expected | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Astellas Pharma Global Development, Inc. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06093425 Comparator | Jun 2026 → Oct 2029 expected | gastric cancer, gastroesophageal junction adenocarcinoma | Suzhou Transcenta Therapeutics Co., Ltd. | Not yet recruiting | No outcome recorded |
| Show all 247 trials opens the full record — a long page | ||||||
| Phase 416 trials | ||||||
| Phase 4 | NCT07094893 Background | Apr 2026 → Mar 2028 expected | colorectal cancer | Gruppo Oncologico del Nord-Ovest | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07446465 Background | Mar 2026 → Jan 2027 expected | colorectal cancer | Ye Xu | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06368063 Comparator | May 2024 → Mar 2026 overdue | pancreas disorder | Xi'an Jiaotong University | Recruiting | No outcome recorded |
| Phase 4 | NCT06311942 Background | Apr 2024 → Dec 2027 expected | hepatocellular carcinoma | Chen Xiaoping | Recruiting | No outcome recorded |
| Phase 4 | NCT06269445 Background | Jan 2024 → Feb 2025 | colorectal cancer | Sir Run Run Shaw Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT05124002 Background | Aug 2022 → Apr 2026 | intrahepatic cholangiocarcinoma | Beijing Tsinghua Chang Gung Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04810585 Background | Apr 2020 → Oct 2025 | colorectal cancer | Yonsei University | Unknown | No outcome recorded |
| Phase 4 | NCT03656549 Background | Feb 2019 → Dec 2023 | mesothelioma, non-small cell lung carcinoma | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT03645187 Comparator | Aug 2018 → Aug 2025 | colon carcinoma | Tanta University | Unknown | No outcome recorded |
| Phase 4 | NCT02366819 Background | Dec 2014 → Jun 2026 | esophageal adenocarcinoma, gastric adenocarcinoma | University of Chicago | Suspended | No outcome recorded |
| Phase 4 | NCT01972490 Background | Oct 2013 → Dec 2017 | colorectal neoplasm | Xu jianmin | Completed | No outcome recorded |
| Phase 4 | NCT01588990 Background | Jun 2012 → Sep 2016 | colorectal cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 4 | NCT03084809 Background | May 2012 → Sep 2014 | colorectal cancer | China Meitan General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01271582 Background | Jan 2009 → Jun 2014 | colorectal cancer, gastric cancer | Asan Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT01564810 Background | Sep 2006 → Jun 2012 | colorectal adenocarcinoma, metastatic malignant neoplasm | Xu jianmin | Unknown | No outcome recorded |
| Phase 4 | NCT00004317 Background | Jul 2000 → Dec 2030 expected | toxoplasmosis | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
| Phase not applicable37 trials | ||||||
| — | NCT07325214 Background | Sep 2026 → Jan 2030 expected | malignant pancreatic neoplasm, pancreatic exocrine neoplasm | IMGT Co., Ltd. | Not yet recruiting | No outcome recorded |
| — | NCT07543510 Background | May 2026 → Aug 2028 expected | hepatocellular carcinoma | Third Affiliated Hospital, Sun Yat-Sen University | Not yet recruiting | No outcome recorded |
| — | NCT07493161 Background | Apr 2026 → Mar 2028 expected | B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| — | NCT07334587 Comparator | Sep 2025 → Feb 2026 overdue | colorectal carcinoma | Allama Iqbal Medical College | Enrolling by invitation | No outcome recorded |
| — | NCT07114666 Background | Aug 2025 → Aug 2029 expected | malignant pancreatic neoplasm | Peking Union Medical College Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06867146 Comparator | Oct 2024 → Dec 2026 expected | malignant pancreatic neoplasm | Peking Union Medical College Hospital | Active not recruiting | No outcome recorded |
| — | NCT06055179 Background | Mar 2024 → Jun 2026 overdue | irinotecan toxicity | Guangzhou University of Traditional Chinese Medicine | Recruiting | No outcome recorded |
| — | NCT07391163 Background | Jan 2024 → Jan 2026 | colorectal cancer | Tanta University | Completed | No outcome recorded |
| — | NCT05718492 Background | Oct 2022 → Oct 2025 overdue | hepatocellular carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| — | NCT05262452 Background | Aug 2021 → Mar 2023 | chemotherapy-induced toxicity, malignant pancreatic neoplasm | Seoul National University Hospital | Unknown | No outcome recorded |
| — | NCT04926545 Background | Jul 2021 → Jul 2024 | cancer, diarrheal disease | Guangzhou University of Traditional Chinese Medicine | Completed | No outcome recorded |
| — | NCT04886193 Background | Apr 2021 → May 2022 | gastric cancer | Guangdong Provincial Hospital of Traditional Chinese Medicine | Unknown | No outcome recorded |
| — | NCT04562558 Background | Sep 2020 → Nov 2024 overdue | choriocarcinoma, invasive hydatidiform mole | xiang yang | Active not recruiting | No outcome recorded |
| — | NCT04595929 Background | Feb 2020 → Oct 2021 overdue | gastric cancer, peritoneal carcinomatosis | St. Petersburg State Pavlov Medical University | Recruiting | No outcome recorded |
| — | NCT03838406 Background | Aug 2017 → Dec 2019 | — | Chung-Ang University | Completed | No outcome recorded |
| — | NCT03690323 Background | Apr 2015 → Nov 2019 | pancreatic exocrine neoplasm | Academic Medical Center - University of Amsterdam | Unknown | No outcome recorded |
| — | NCT03121807 Background | Sep 2014 → Apr 2019 | gastric cancer | Kaohsiung Medical University Chung-Ho Memorial Hospital | Completed | No outcome recorded |
| — | NCT02256800 Background | Aug 2014 → Nov 2017 | colorectal cancer | Jaw-Yuan Wang, MD, PhD | Completed | No outcome recorded |
| — | NCT01941173 Background | Jan → Jul 2014 | rectal cancer | City of Hope Medical Center | Withdrawn | No outcome recorded |
| — | NCT01411072 Background | Sep 2011 → Sep 2015 | malignant pancreatic neoplasm | AHS Cancer Control Alberta | Unknown | No outcome recorded |
| — | NCT00673179 Background | May 2008 → Nov 2010 | osteosarcoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| — | NCT00724503 Comparator | Aug 2006 → May 2015 | colorectal carcinoma, metastasis from malignant tumor of colon | Sirtex Medical | Completed | No outcome recorded |
| — | NCT00550992 Background | Jan 2006 → Dec 2020 | leukemia | Dutch Childhood Oncology Group | Unknown | No outcome recorded |
| — | NCT00096135 Background | Nov 2004 → Sep 2013 | leukemia | Children's Oncology Group | Completed | No outcome recorded |
| — | NCT00317408 Background | Apr 2004 → Feb 2014 | lymphoma | European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma | Unknown | No outcome recorded |
| — | NCT00416819 Background | Sep 2003 → Dec 2005 | central nervous system neoplasm, lymphoma | University of California, San Francisco | Completed | No outcome recorded |
| — | NCT00049569 Background | Jan 2003 → Mar 2006 | T-cell childhood acute lymphocytic leukemia | National Cancer Institute (NCI) | Completed | No outcome recorded |
| — | NCT00594815 Background | Aug 2002 → Feb 2016 | lymphoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| — | NCT00016302 Background | Apr 2001 → Jul 2007 | T-cell childhood acute lymphocytic leukemia | National Cancer Institute (NCI) | Completed | No outcome recorded |
| — | NCT00004891 Background | Sep 1999 → Mar 2007 | colorectal cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| — | NCT00002102 Background | — | HIV infectious disease, pneumocystosis | U.S. Bioscience | Completed | No outcome recorded |
| — | NCT00000674 Background | ? → Aug 1992 | HIV infectious disease, cerebral toxoplasmosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| — | NCT00002103 Background | — | HIV infectious disease, pneumocystosis | U.S. Bioscience | Completed | No outcome recorded |
| — | NCT00000723 Background | ? → Mar 1990 | HIV infectious disease, non-Hodgkin lymphoma | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| — | NCT00000703 Background | ? → Mar 1990 | HIV infectious disease, non-Hodgkin lymphoma | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| — | NCT00002317 Background | — | HIV infectious disease, pneumocystosis | U.S. Bioscience | Completed | No outcome recorded |
| — | NCT00002434 Background | — | HIV infectious disease, pneumocystosis | U.S. Bioscience | Completed | No outcome recorded |
| Phase not stated2 trials | ||||||
| — | NCT04446793 Background | — | colorectal cancer | Cardiff Oncology | No longer available | No outcome recorded |
| — | NCT00517894 Background | — | lymphoma | Study Group of Medical Tumour Therapy (AGMT) | No longer available | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2016-10-18 | Takeda | Shire Granted EU Marketing Authorization of ONIVYDE®, In Combination With 5-Fluorouracil (5-FU) And Leucovorin (LV), For The Treatment of Metastatic Adenocarcinoma Of The Pancreas in Adult Patients Who Have Progressed Following Gemcitabine-Based Therapy takeda.com ↗ |
Evidence & citations 46 cited values
Every value below carries the sentence it was read from. 1,891 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Leucovorin | “Adjuvant chemotherapy: FOLFOX6 regiment : Oxaliplatin（Hengrui Medicine Co., Ltd，China） 85mg/m2 IV d1, Leucovorin （Hengrui Medicine Co., Ltd，China）400mg/m2 IV d1, 5-FU（Hengrui...” NCT01889303 ↗1291“Cetuximab 500mg/m² + envafolimab 200mg + irinotecan 150 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h all on day 1 of each 2 weeks cycle up to...” NCT05959356 ↗ “Patients will be randomized to receive 5 cycles of combination chemotherapy (5-FU, adriamycin, leucovorin, cytoxan, G-CSF) either as initial therapy (preoperative) or...” NCT00001250 ↗ “Oxaliplatin 85 mg/m2 intravenously on day 1; Leucovorin 200 mg/m2 IV(in vein) from hour 0 to 2 on days 1 and 2; and Fluorouracil 400 mg/m2 IV bolus at hour 2, then 600mg/m2...” NCT02527772 ↗ “It will comprise irinotecan, 180 mg/m2 IV infusion over 30 to 120 minutes; leucovorin, 400 mg/m2 IV infusion to match the duration of the irinotecan infusion; and 5-FU, 400...” NCT01124630 ↗ “Randomization to receive 400 mg sorafenib twice daily (sorafenib group) or 400 mg sorafenib twice daily plus HAIC (SoraHAIC group) (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2,...” PMID 31070690 ↗ Jul 2019 “The FOLFOXIRI chemotherapy regimen (5-fluorouracil, leucovorin, oxaliplatin, irinotecan) will be administered according to the study protocol as part of total neoadjuvant...” NCT07277842 ↗ “Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV...” NCT04084496 ↗ “The FOLFIRINOX regimen consists of oxaliplatin given as a 2-hour intravenous infusion, immediately followed by leucovorin given as a 2-hour intra-venous infusion, with the...” NCT03042780 ↗ “This study will assess the safety and pharmacokinetics of adding dulanermin to Camptosar®/Erbitux® or the FOLFIRI regimen (Camptosar®, 5-FU, and leucovorin) plus bevacizumab...” NCT00671372 ↗ “The mFOLFOX regimen was administered via hepatic artery: oxaliplatin , 85mg/m2 , from hour 0 to 2 on day1 ; leucovorin , 400mg/m2 , from hour 2 to 3 on day 1 ; fluorouracil ,...” NCT05007587 ↗ “FOLFIRI (180 mg/m\^2 irinotecan, 400 mg/m\^2 leucovorin, 400 mg/m\^2 bolus 5-fluorouracil \[5-FU\], and 2400 mg/m\^2 continuous intravenous infusion 5-FU over 46 hours) will be...” NCT04446793 ↗ “Participants enrolled will receive QL1706 (5 mg/kg, Q3W, d1) + docetaxel (50 mg/m², Q3W, d1) + oxaliplatin (100 mg/m², Q3W, d1) + leucovorin (LV) (400 mg/m², Q3W, d1) +...” NCT07400315 ↗ “NALIRIFOX (liposomal irinotecan 50 mg/m2, oxaliplatin 60 mg/m2, leucovorin 400 mg/m2, and fluorouracil 2400 mg/m2, administered sequentially as a continuous intravenous...” NCT06429904 ↗ “Nanoliposomal irinotecan plus fluorouracil/leucovorin chemotherapy will be administered in Cycle 2 and Cycles ≥ 4 of the Treatment Period to patients who progressed on nab...” NCT04037241 ↗ “mFOLFOX6 plus Cetuximab Induction therapy：Oxaliplatin ivgtt 85mg/m2, D1 + Leucovorin ivgtt 400mg/m2, D1 + Fluorouracil iv bolus 400mg/m2, D1 + Fluorouracil 2400mg/m2 continuous...” NCT06616259 ↗ “HAIC with FOLFOX regimen (oxaliplatin 85 mg/m2 at hours 0-2, leucovorin 400 mg/m2 at hours 2-3, and fluorouracil 400 mg/m2 at hour 3, followed by fluorouracil 2400 mg/m2 for 46...” PMID 40335980 ↗ May 2025 “This regimen consists of oxaliplatin 85 mg/m2 IV given over 2 hours, leucovorin 400 mg/m2 IV given over 2 hours, and fluorouracil 400 mg/m2 IV bolus, followed by fluorouracil...” NCT05575635 ↗ “BACKGROUND: FOLFIRI (irinotecan, 5-fluorouracil, and leucovorin) + aflibercept improves median overall survival (OS) and progression-free survival (PFS) in patients with...” PMID 32921581 ↗ Jun 2020 “This regimen consists of oxaliplatin 85 mg/m2 IV given over 2 hours, leucovorin 400 mg/m2 IV given over 2 hours, and fluorouracil 400 mg/m2 IV bolus, followed by fluorouracil...” NCT00779311 ↗ “FOLFIRINOX: oxaliplatin 85 mg/m\^2, irinotecan 180 mg/m\^2, leucovorin 400 mg/m\^2 and fluorouracil 400 mg/m\^2 given as a bolus followed by 2400 mg/m\^2 given as a 46-hour...” NCT06278454 ↗ “The study focuses on advanced metastatic pancreatic cancer, testing a combination of low-dose anti-cancer drugs (G-FLIP: Gemcitabine, Fluorouracil, Leucovorin, Irinotecan, and...” NCT06233877 ↗ “Chemotherapy combination of leucovorin administered as an IV injection, 5-fluorouracil (5-FU) administered as IV bolus injection or IV continuous infusion (depending on dose),...” NCT04185883 ↗ “5-fluorouracil/oxaliplatin (FOLFOX): oxaliplatin 80mg/m2 (80% dose of 100mg/m2) iv ov 120min, leucovorin 80mg/m2 (80% dose of 100mg/m2) iv ov 120min, 5-fluorouracil 1900mg/m2...” NCT02114359 ↗ “Standard of care, gemcitabine-based regimen (single-agent gemcitabine or gemcitabine plus erlotinib) or FOLFIRINOX (combination chemotherapy regimen including 5-fluorouracil,...” NCT01505530 ↗ “The objective of this study was to evaluate safety and anti-tumour activity of fluorouracil, leucovorin, irinotecan plus oxaliplatin (FOLFIRINOX) as salvage treatment in...” PMID 31919404 ↗ Jan 2020 “To evaluate the safety and effectiveness of a novel neoadjuvant treatment strategy incorporating 5-fluorouracil/leucovorin with oxaliplatin ( FOLFOX )chemotherapy in...” NCT02243358 ↗ “Once eligibility has been confirmed and the patient has been registered to the study, the patient will begin induction modified FOLFIRINOX (Oxaliplatin, Leucovorin, Irinotecan,...” NCT05132504 ↗ “Oxaliplatin 85 mg/m2 on day 1; irinotecan 150 mg/m2 on day 1; leucovorin 400 mg/m2 on day 1; fluorouracil 2400 mg/m2 civ over 46h; treatment will be repeated every 14 days;...” NCT03975049 ↗ “Patients with an unresectable metastatic colorectal carcinoma (mCRC) histologically proven will be treated with a combination of...” NCT02173990 ↗ “FOLFOX consisted of oxaliplatin 85 mg/m2 on D1, leucovorin 400 mg/m2 on D1, 5-fluorouracil 400 mg/m2 intravenous bolus on D1 and 5-fluorouracil 1200 mg/m2/day continuous...” NCT01786538 ↗ “this study is an investigator-initiated single-arm, phase II trial to investigate the efficacy of PIPAC combined with systemic FOLFOX (5-fluorouracil, oxaliplatin, leucovorin)...” PMID 37875869 ↗ Oct 2023 “Arm A will receive only systemic chemotherapy according to this scheme: Oxaliplatin 85 mg/m2, d1, over 2 h, Leucovorin 400 mg/m2, d1 i.v. over 2 h, 5-FU 400 mg/m2 in bolus and...” NCT05303714 ↗ “FOLFIRI chemotherapy was initiated on Day 1 of each treatment cycle at the following starting doses: irinotecan 180 mg/m², leucovorin 400 mg/m², 5-fluorouracil bolus 400 mg/m²,...” NCT00508404 ↗ “However, a recent Phase I/II study demonstrated tolerability of the chemotherapy combination liposomal irinotecan, oxaliplatin, 5-fluorouracil, and leucovorin (NALIRIFOX) in...” NCT07076212 ↗ “mDOF(docetaxel 50 mg/ m2 day 1 + oxaliplatin 85 mg/ m2 day 2 + fluorouracil 400 mg/ m2 bolus iv followed by 600 mg/ m2 22 hours chronic infusion, day 2/3 + leucovorin 200 mg/...” NCT02960061 ↗ “Study participants will receive predefined doses of oxaliplatin, Leucovorin and 5-fluorouracil as part of the mFOLFOX6 chemotherapy regimen administered as intravenous (iv)...” NCT04393298 ↗ “G-FLIP regimen is a combination of low doses (doses lower than those approved by the FDA and used in the clinic) of several anti-cancer drugs, Gemcitabine, Fluorouracil,...” NCT01905150 ↗ “All patients will be planned for six two-weekly cycles of FOLFOXIRI (5-fluorouracil, leucovorin, oxaliplatin and irinotecan) prior to chemoradiotherapy (25 × 2 Gy or 28 × 1.8...” PMID 36068495 ↗ Sep 2022 “irinotecan 150 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 3000 mg/m² cont. inf. + panitumumab, iv, 6 mg/kg BW all on day 1 of each 2 weeks cycle until PD or...” NCT01328171 ↗ “The "oxaliplatin-based" group will receive gemox (gemcitabine-oxaliplatin, 1x/2 week); alternatively folfox (5 fluorouracil-leucovorin-oxaliplatin, 1x/2 week) or capox...” NCT03217097 ↗ “A Phase II Study Of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), Leucovorin (CF), and Cetuximab (C225) For Patients With Unresectable Hepatic Metastases From Metastatic...” NCT00056030 ↗ “combined with fluorouracil plus leucovorin, oxaliplatin, and albumin bound paclitaxel (Nab-POF) regimen in the treatment of patients with unresectable locally advanced or...” NCT04510064 ↗ “Bevacizumab 5mg/kg + irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or...” NCT02350530 ↗ “Cetuximab 500mg/m² + irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or...” NCT02063529 ↗ “Oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil bolus 400 mg/m2 on day 1, and 5-fluorouracil infusion 2400 mg/m2 for 48 h) every 2 weeks for total 6 cycles...” NCT05792735 ↗ “oxaliplatin 85 mg/m² IV, leucovorin 200 mg/m² IV (or folinic acid 400 mg/m²), and fluorouracil (5-FU) 400 mg/m² IV bolus; followed by 5 FU 2400 mg/m² as a 46 hour continuous IV...” NCT06529718 ↗ “Folfox(Oxaliplatin 85mg/m2 iv Day1; Leucovorin 400mg/m2 iv Day1; 5-FU 400mg/m2 iv bolus on Day1, then1200mg/m2/d x 2days(total 2400mg/m2 over 46-48 hours) iv continuous...” NCT03985891 ↗ “Liposomal Irinotecan (Nal-IRI) Plus 5-fluorouracil and Leucovorin (5-FU/LV) Plus Oxaliplatin (NALIRIFOX) as First-Line Chemotherapy for Patients With Advanced Small Intestine...” NCT07060014 ↗ “Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Versus Cetuximab as Maintenance Therapy in First-Line Therapy for RAS and BRAF Wild-Type Metastatic Colorectal Cancer:...” PMID 38181312 ↗ Jan 2024 “In the experimental arm, patients will be treated with irinotecan 180 mg/m2 + leucovorin 400 mg/m2 at day 1 then 5-FU 400 mg/m2 bolus followed by 2400 mg/m2 continuous infusion...” NCT06501482 ↗ “FOLFOX4(Oxaliplatin + 5-Fluorouracil/Leucovorin): 4 weeks after HR; Drug: Oxaliplatin + 5- Fluorouracil/Leucovorin Day 1: Oxaliplatin 85mg/m² 2h IV infusion, leucovorin...” NCT02452853 ↗ “Drug used in chemotherapy such as oxaliplatin leucovorin and Fluorouracil work in different way to stop the growth of tumor cells either by killing the cells or by stopping...” NCT00578201 ↗ “PURPOSE: To assess the effects of bevacizumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) as first-line treatment of RAS mutant unresectable colorectal...” PMID 32749938 ↗ Aug 2020 “NALIRIFOX (liposomal irinotecan 50 mg/m2, oxaliplatin 60 mg/m2, leucovorin 400 mg/m2, and fluorouracil 2400 mg/m2, administered sequentially as a continuous intravenous...” PMID 37708904 ↗ Sep 2023 “FOLFIRINOX consisting of Oxaliplatin 85 mg/m\^2 IV over 2 hours; Irinotecan 180 mg/m\^2 IV over 90 minutes; Leucovorin 400 mg/m\^2 IV over 2 hours; Fluorouracil 2.4 g/m\^2 IV...” NCT01836432 ↗ “The purpose of this study is to test the safety, activity and best doses of FOLFOX-A which consists of the standard chemotherapy drugs fluorouracil, leucovorin, oxaliplatin and...” NCT01744353 ↗ “folinic acid (also called leucovorin, calcium folinate or FA) fluorouracil (also called 5FU) irinotecan given per institutional standard (intravenously day 1 and day 15 of 28 day cycle)” NCT04587128 ↗ “Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for untreated advanced or metastatic pancreatic ductal adenocarcinoma.” PMID 40619376 ↗ Jul 2025 “Hepatic arterial infusion chemotherapy with FOLFOX regimen (oxaliplatin 85 mg/m², leucovorin 400 mg/m², fluorouracil 400 mg/m² bolus then 2400 mg/m² continuous infusion over 24 hours).” NCT07543783 ↗ “A Phase II Study of Weekly Paclitaxel(Taxol)and 24-Hour Infusion High-Dose 5-Fluorouracil and Leucovorin(HDFL)in the Treatment Locally Advanced and Recurrent/Metastatic Gastric Cancers” NCT00154726 ↗ “mFOLFOX6 consisting of Folinic acid (Leucovorin) 400 mg/m2 (D,L racemic form) or 200 mg/m2 (L-isomer form [levo leucovorin]), 5-fluorouracil (5-FU) 2400 mg/m2 and Oxaliplatin 85 mg/m2” NCT05052099 ↗ “NALIRIFOX is a chemotherapy regimen that includes liposomal irinotecan, oxaliplatin, 5-fluorouracil (5-FU), and leucovorin, administered intravenously in 10-12 cycles every two weeks.” NCT07173387 ↗ “oxaliplatin 85 mg/m2, leucovorin 400 mg/m2 and fluorouracil 400 mg/m2 IV, fluorouracil 2400 mg/m2 IV (a 46 hrs CI), day 1 of each treatment cycle, every 2 weeks, given with nivolumab” NCT03921684 ↗ “Chemotherapy regimen FULIRI: Irinotecan liposome 70 mg/m2; leucovorin CF 400 mg/m2, d1, iv drop; 5-FU 400 mg/m2, d1, iv drop; 5-FU 2400 mg/m2, d1, CIV 46-48h; repeated every 2 weeks.” NCT07515963 ↗ “In 2011, the PRODIGE trial has shown that oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) was associated with a survival advantage but had increased toxicity.” NCT06249321 ↗ “It's a combination of drugs that are already approved to treat pancreatic cancer: Liposomal irinotecan (Nal-IRI or Onivyde®), 5 fluorouracil (5-FU)/leucovorin, and Oxaliplatin.” NCT07030283 ↗ “liposomal irinotecan 50 mg/m², oxaliplatin 60 mg/m², leucovorin 400 mg/m², and fluorouracil 2400 mg/m², administered sequentially as a continuous intravenous infusion over 46 h” NCT05859750 ↗ “Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial.” PMID 34648352 ↗ Oct 2021 “oxaliplatin ivgtt 85mg/m2 d1+ leucovorin ivgtt 400mg/m2 d1+ fluorouracil iv bolus 400mg/m2 d1+ fluorouracil 2400mg/m2 continuous infusion for 46h+cetuximab ivgtt 500mg/m2, q2w” NCT05022030 ↗ “folinic acid (also known as: 5-formyl tetrahydrofolic acid and leucovorin) intravenous infusion, and 5-FU (also known as; fluorouracil) intravenous bolus/intravenous infusion” NCT05004350 ↗ “FOLFOXIRI+Cetuximab Irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h +Cetuximab 500mg/m²,all on day 1 of each 2 weeks cycle” NCT03391843 ↗ “Irinotecan 180 mg/m2 Day 1 Oxaliplatin 85 mg/m2 Day 1 5-FU 400 mg/m2 bolus with Leucovorin 200 mg/m2 over 2h, Day 1, then 5-FU 2400 mg/m2 over 46h. Four cycles, if tolerated” NCT01839799 ↗ “Investigator's choice of one of the following commercially available products: gemcitabine; capecitabine; fluorouracil with or without leucovorin; irinotecan; or erlotinib.” NCT02004262 ↗ “intravenous liposomal irinotecan (70 mg/m2 for 90 min) plus intravenous leucovorin (400 mg/m2 for 30 min) and intravenous fluorouracil (2400 mg/m2 for 46 h) every 2 weeks” PMID 34656226 ↗ Oct 2021 “FOLFIRI (Irinotecan,180 mg/m2 IV over 90 minutes; 5-Fluorouracil l400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hours; Leucovorin 200-400c mg/m2 IV over 2 hours)” NCT01298570 ↗ “The FLOT regimen consisted of four cycles of 5-Fluorouracil 2600 mg/m2, Leucovorin 200 mg/m2, Oxaliplatin 85 mg/m2, and Docetaxel 50 mg/m2, intravenous every 2 weeks.” PMID 41181842 ↗ Oct 2025 “A 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2), administered simultaneously over a 2-hour infusion period.” NCT04149015 ↗ “A 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2), administered simultaneously over a 2-hour infusion period.” NCT03788226 ↗ “FOLFOX chemotherapy with oxaliplatin (85 mg/m2 IV), leucovorin (400 mg/m2 IV), 5-FU (400 mg/m2 IV bolus), and 5-FU (2400 mg/m2/day continuous IV infusion over 48 h).” NCT04757363 ↗ “Oxaliplatin 85 mg/m² 2h day 1, 15, 29 plus Leucovorin 400 mg/m² 2h day 1, 15, 29 plus 5-FU 400 mg/m² bolus, followed by 2.400 mg/m² 46h day 1, 15, 29; Q6W, 2 cycles” NCT05268510 ↗ “Perioperative FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) is a standard therapy for resectable gastric and gastroesophageal junction adenocarcinomas” PMID 40454643 ↗ Jun 2025 “The regimen consists of Oxaliplatin 85 mg/m², Leucovorin 400 mg/m², and 5-Fluorouracil 2500 mg/m² given as a continuous hepatic arterial infusion over 46-48 hours.” NCT07483359 ↗ “The mFOLFIRI.3 regimen consisted of irinotecan (70 mg m(-2); days 1 and 3), leucovorin (400 mg m(-2); day 1), and 5-FU (2000 mg m(-2); days 1 and 2) every 2 weeks.” PMID 19826418 ↗ Oct 2009 “Modified oxaliplatin, leucovorin, irinotecan and fluorouracil (mFOLFIRINOX) will be administered intravenously within 2 days after administration of zolbetuximab.” NCT06396091 ↗ “continuous intravenous infusion of fluorouracil 2400mg / m², for 46 hours, leucovorin 400mg / m², irinotecan 135mg / m², and oxaliplatin 68mg / m², every 2 weeks” NCT06888648 ↗ “Includes Hepatic Arterial Infusion Chemotherapy (HAIC) with mFOLFOX6 (Oxaliplatin, Leucovorin, Fluorouracil), oral Lenvatinib, and an intravenous PD-1 inhibitor.” NCT07282184 ↗ “FOLFOX4 chemotherapy：5-FU 400 mg/m2 i.v. bolus and Leucovorin 200 mg/m2 i.v. followed by 5-FU 600 mg/m2 i.v. 22 h-infusion day 1 + 2, oxaliplatin 85 mg/m2 day 1” NCT02941562 ↗ “Sorafenib is used in combination with irinotecan, leucovorin and fluorouracil in patients with advanced colorectal cancer after failure of oxaliplatin treatment” NCT00839111 ↗ “The subjects will be administered folinic acid (Leucovorin; LV), Fluorouracil (5-FU) and Oxaliplatin (FOLFOX) + Bevacizumab/Cetuximab by intravenous infusion.” NCT02826837 ↗ “Bevacizumab 5mg/kg D1, oxaliplatin 85 mg/m2 D1 + leucovorin 400mg/m2 D1 + irinotecan 150 mg/m2 D1 + 5-FU 2,400 mg/m2 46h continuous infusion, every other week” NCT05665023 ↗ “Oxaliplatin 85 mg/M2 IV on Day 1 Leucovorin 400 mg/m2 IV on Day 1 5-FU 400 mg/m2 IV bolus followed by 2400 mg/m2 IV continuous infusion over 46 hours Days 1-3” NCT01489865 ↗ “Leucovorin 180 mg/m2 IV beginning 36 hours after start of methotrexate infusion and then 12 mg/m2 IV every 6 hours until methotrexate level is below 0.01 nM.” NCT00450801 ↗ “FOLFOX4 was administered by oxaliplatin 85 mg/m² d1+ leucovorin 200 mg/m² d1-2+ fluorouracil 400 mg/m² 2 h→ 600 mg/m² 24 h d1-2 q2w, with a total of 4 cycles” NCT06893887 ↗ “Irinotecan 180 mg/m2 on day 1 and 5-FU 400 mg/m2 on day 1 and Leucovorin 400 mg/m2 day 1 and 5-FU 2400 mg/m2 over 46 hours, days 1-3 as a continuous infusion” NCT01888978 ↗ “Patients receive oxaliplatin IV over 2 hours on day 1 and leucovorin calcium IV over 2 hours and fluorouracil IV continuously over 22 hours on days 1 and 2.” NCT00265811 ↗ “HAIC- modified FOLFOX (oxaliplatin, 85 mg/m2; leucovorin, 400 mg/m2; 5-fluorouracil bolus, 400 mg/m2 on day 1; 5-fluorouracil infusion, 2400 mg/m2 for 46 h)” NCT06364007 ↗ “Patients receive oxaliplatin 85 mg/m\^2 IV infused over two hours followed by leucovorin 400 mg/m\^2 IV over 2 hours followed by 5-FU 400 mg/m\^2 IV bolus” NCT00265850 ↗ “mFOLFOX6 (oxaliplatin 85mg/m2 IV, leucovorin 400mg/m2 IV, 5-Fluorouracil bolus 400mg/m2 IV, and 5-Fluorouracil 2400mg/m2 IV) on day 1 of each 14 day cycle” NCT01652976 ↗ “the control group (n=28) which received 6 cycles of folinic acid, fluorouracil and irinotecan (FOLFIRI) regimen (5-flourouracil, leucovorin, irinotecan)” PMID 35022282 ↗ Jan 2022 “Participants receiving mFOLFOX6 regimen of chemotherapy will receive an IV infusion of Folinic acid (leucovorin or local equivalent) once every 2 weeks.” NCT06901531 ↗ “FOLFOX-based regimen for hepatic arterial infusion chemotherapy: oxaliplatin, 85 mg/m2 infusion for 2 hours; leucovorin, 400 mg/m2 infusion for 2 hours” NCT05263219 ↗ “mFOLFIRINOX- IV oxaliplatin 85 mg/m2; IV leucovorin 400 mg/m2; IV irinotecan 150 mg/m2; 5-FU 2400 mg/m2 by 46-hour infusion, per local standard of care” NCT07280377 ↗ “FLOX: Intravenous oxaliplatin 85 mg/m2 on day 1; bolus 5-fluorouracil 500 mg/m2 and bolus Leucovorin on days 1 and 2; IV administration every 2 weeks.” NCT03388190 ↗ “FOLFOX (folinic acid \[FOL, leucovorin\], fluorouracil \[F, 5-FU\], and oxaliplatin \[OX\]) was supplied as solutions for intravenous administration.” NCT00959647 ↗ “consists of 5-Fluorouracil (5-FU) 400 mg/m\^2, 5-FU continuous IV 2400 mg/m\^2 over 46 hours, leucovorin 400 mg/m\^2 IV, and oxaliplatin 85 mg/m\^2.” NCT01611857 ↗ “Chemotherapy preferably CapOx (capecitabine + oxaliplatin) or FOLFOX (5-fluoruracil, leucovorin and oxaliplatin) will be combined with immunotherapy” NCT07000253 ↗ “chemotherapy drugs (oxaliplatin, fluorouracil and leucovorin; FOLFOX-based regimen) will be intra-arterially administered though the microcatheter.” NCT06904183 ↗ “FOLFIRINOX protocol (oxaliplatin 85 mg/mq and irinotecan 180 mg/mq plus leucovorin 400 mg/mq followed by bolus fluorouracil (FU) 400 mg/mq on day 1” NCT05399394 ↗ “5-fluorouracil \[continuous infusion\], leucovorin \[administered IV\] (or levoleucovorin \[administered IV\]), and oxaliplatin \[administered IV\]” NCT04952753 ↗ “chemotherapy drugs (oxaliplatin, fluorouracil and leucovorin; FOLFOX-based regimen) will be intra-arterially administered though the microcatheter.” NCT06492395 ↗ “Combination of chemotherapy administered every 2 weeks: oxaliplatin (85mg/m2), 5-Fluorouracil (2400mg/m2) and folinic acid (=leucovorin, 400mg/m2)” NCT03176264 ↗ “FOLFOX4 regimen: Oxaliplatin 85mg/m2 intravenous infusion over 2 hours on Day 1; Leucovorin 400mg/m2 intravenous infusion over 2 hours on Days 1-2” NCT06409637 ↗ “Oxaliplatin 85 mg/m2 + Leucovorin 400 mg/m2 IV, followed by 5-FU 400 mg/m2 IV, followed 5-FU 2400 mg/m2 IV by continuous infusion over 46 hours” NCT01363843 ↗ “mFOLFOX6 (oxaliplatin 85 mg/m\^2, leucovorin 400 mg/m\^2 and 5FU (fluorouracil) 400 mg/m\^2 bolus followed by 2400 mg/m\^2 continuous infusion)” NCT02648711 ↗ “mFOLFIRI is a standardized chemotherapy regimen utilizing 5-fluorouracil, leucovorin, and irinotecan administered on day one of a 14-day cycle.” NCT04158349 ↗ “5-FU/LV + bevacizumab (following FOLFOX-B) Bevacizumab 5.0mg/kg i.v. together with leucovorin 400 mg/m2 i.v. bolus 5FU 400 mg/m2 all on day 1.” NCT05375708 ↗ “leucovorin - a form of Folic acid helps the body produce and maintain new cells, and also helps prevent changes to DNA that may lead to cancer” NCT06896188 ↗ “Combination chemotherapy consists of Flurouricil, Leucovorin, Adriamycin, and Cytoxan (FLAC) which will be given every 21 days for 10 cycles.” NCT00001239 ↗ “standard first-line leucovorin/5-FU/oxaliplatin (FOLFOX6)/bevacizumab (FOLFOX/BEV) every 2 weeks with (n = 51) or without (n = 52) pelareorep” PMID 29653857 ↗ Mar 2018 “FOLFIRINOX (oxaliplatin 85 mg/m2, irinotecan 180 mg/m2, leucovorin 400 mg/m2, and 5-fluorouracil (400 mg/m2 bolus then 2400 mg/m2 over 46 h))” NCT07155629 ↗ “The FOLFOX regimen consisted of oxaliplatin 85 mg/m\^2 intravenous (IV) infusion on Day 1, leucovorin, 200 mg/m\^2 (racemate) on Days 1 and 2” NCT00364013 ↗ “Induction (2 cycles): Vincristine, Prednis(ol)one, Methotrexate, Leucovorin, Cyclophosphamide, Doxorubicin, IT medications, G-CSF, Rituximab” NCT01046825 ↗ “FOLFOX: Leucovorin 400 mg/m2, day 1, fluorouracil 400 mg/m2, day 1 and 1200 mg/m2, days 1-2, and oxaliplatin 85 mg/m2, day 1, every 2 weeks.” NCT06121700 ↗ “in combination with leucovorin or levoleucovorin (LV) IV administered per local guidelines and/or prescribing information once every 2 weeks” NCT05609370 ↗ “preoperative radiation and 5-fluorouracil-based chemotherapy (5,040 cGy to the pelvis and 2 cycles of bolus 5-fluorouracil with leucovorin)” PMID 10813118 ↗ Jan 2000 “irinotecan liposomes with oxaliplatin, 5-fluorouracil (5-FU) / leucovorin (LV) with or without adelizumab for resectable pancreatic cancer” NCT06172036 ↗ “The regimen of mFOLFOX treatment includes, Oxaliplatin 85 mg/m2 IV day 1, Leucovorin 400 mg/m2 IV day 1, 5-FU 400 mg/m2 IV bolus on day 1” NCT05484024 ↗ “90-min IV infusion of irinotecan, leucovorin, and fluorouracil followed by a continuous 46-hour infusion of fluorouracil every two weeks” NCT05480306 ↗ “FOLFOX-HAIC（oxaliplatin, 130 mg/m2 and leucovorin, 200 mg/m2, and fluorouracil, 400 mg/m2, bolus and 2400 mg/m2 over 46 hours Q3W D2 D3)” NCT03869034 ↗ “irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle” NCT02217020 ↗ “The first-line therapy will be 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) or best available standard of care.” NCT03322995 ↗ “irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle” NCT03161574 ↗ “The chemotherapy schedule will include administration of FOLFIRINOX (5-Fluorouracil, Irinotecan, Oxaliplatin, and Leucovorin) will be:” NCT02592395 ↗ “mFOLFOX6 is combination of folinic acid (FOL)/leucovorin, 5-fluorouracil and oxaliplatin (OX) which acts as systemic cytotoxic agent.” NCT03250832 ↗ “Modified FOLFOX6 regimen consists of 2-hour infusion of oxaliplatin (85 mg/m2) and 2-hour infusion of leucovorin (400 mg/m2) on Day l” NCT04293419 ↗ “Combination of 4 different drugs (5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan and Leucovorin) administered by intravenous infusion” NCT05077800 ↗ “immediately followed by leucovorin at a dose of 400 mg per square meter, given as a 2-hour intravenous infusion through a Y-connector” NCT02440958 ↗ “Patients will receive irinotecan 150 mg/m2 intravenously, in combination with leucovorin and 5-fluorouracil, on day 1 every 2 weeks.” NCT00509964 ↗ “The mFOLFOX6 regimen is: oxaliplatin, calcium leucovorin, 5-fluorouracil, bevacizumab, One cycle is every 2 weeks, lasting 2 cycles.” NCT06491355 ↗ “Leucovorin, 400 mg/m2, intravenous, day 1 Irinotecan, 150 mg/m2, intravenous, day 1 fluorouracil, 2,400 mg/m2, intravenous, day 1-2” NCT04986930 ↗ “Oxaliplatin-based Chemotherapy Every 2 Week Regimens (Q2W Cycles) consisting of Oxaliplatin, Leucovorin (LV), 5-Fluorouracil (5-FU)” NCT00115765 ↗ “It consists of irinotecan, leucovorin, and fluorouracil (5-FU) administered sequentially over a 46-hour infusion period per cycle.” NCT07381309 ↗ “Oxaliplatin, 85 mg/m2, iv, d1; Leucovorin, 400 mg/m2, iv, d1; 5-FU, 400mg/m2, iv, d1 followed by 1200 mg/(m2·d)\*2d, civ, 46h; q2w” NCT05193292 ↗ “Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU).” NCT00422864 ↗ “HAIC: Irinotecan liposome 30 mg/m2, leucovorin 200 mg/m2, 5-FU 200 mg/m2 bolus followed by continuous infusion of 5-FU 1200 mg/m2” NCT06375642 ↗ “Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU)” NCT01013805 ↗ “Oxaliplatin 85mg/m2, Leucovorin 200mg/m2, Irinotecan 180mg/m2, 5-FU 400mg/m2 bolus followed by 2400mg/m2 continuous infusion.” NCT03825861 ↗ “Leucovorin - dose is 400 mg / m2 - this is given at same time with irinotecan (below) and the infusion takes about 1.5 hours.” NCT05121038 ↗ “Standard of Care FOLFOX regimen consists of 8 cycles (each cycle is 14 days) of 5-fluorouracil, leucovorin, and oxaliplatin.” NCT05108428 ↗ “Neoadjuvant chemotherapy with 2 months of combination oxaliplatin and 5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX)” NCT04643366 ↗ “Drug: FOLFOX Protocol (Oxaliplatin, fluorouracil, and leucovorin); Camrelizumab for injection and Apatinib-Mesylate Tablets” NCT05313282 ↗ “Drug: FOLFOX Protocol (Oxaliplatin, fluorouracil, and leucovorin); Camrelizumab for injection and Apatinib-Mesylate Tablets” NCT04191889 ↗ “Onartuzumab (MetMAb) in combination with mFOLFOX6 (modified 5-fluorouracil, folinic acid \[leucovorin\], and oxaliplatin)” NCT01590719 ↗ “Oxaliplatin 85 mg/m² IV, leucovorin 400 mg/m² IV, followed by 5-fluorouracil bolus and continuous infusion every 2 weeks.” NCT07391163 ↗ “oxaliplatin 85 mg/m2 , leucovorin 400 mg/m2 , and fluorouracil 400 mg/m2 administered IV on Day 1 of each treatment cycle” NCT06346197 ↗ “FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) IV will be administered as per schedule specified in the respective arm.” NCT04929223 ↗ “Standard treatment includes the chemotherapy combination of 5-FU, Leucovorin and Oxaliplatin (FOLFOX) with bevacizumab.” NCT01516216 ↗ “mFOLFOX6 is a standard oxaliplatin-based chemotherapy regimen composed of oxaliplatin, leucovorin, and 5-fluorouracil.” NCT07175636 ↗ “FOLFIRI regimen [leucovorin, 5-fluorouracil, and irinotecan] with/without bevacizumab on Days 1/15 of a 28-day cycle” PMID 38036720 ↗ Nov 2023 “Oxaliplatin 85 mg/m² + Leucovorin 200 mg/m² + Irinotecan 180 mg/m² + 5FU bolus 400mg/m² + 5FU continuous 2400 mg/m²” NCT04570943 ↗ “irinotecan 180mg/m2 d1,leucovorin 400mg/m2 d1, 5-fluorouracil 400mg/m2 iv, 2.4g/m2 civ 46h, repeated every 2 weeks” NCT01736904 ↗ “Patients receive adjuvant chemotherapy every 2 weeks during 6 months: FOLFOX6m (5-FU, leucovorin and oxaliplatin).” NCT04120701 ↗ “R-MC -Rituximab (375 mg/m2),Methotrexate (200 mg/m2 - 800mg/m2), Cytarabine (3000mg/m2), Leucovorin (15mg - 50mg).” NCT01854372 ↗ “irinotecan 180mg/m2 d1,leucovorin 400mg/m2 d1, 5-fluorouracil 400mg/m2 iv, 2.4g/m2 civ 46h, repeated every 2 weeks” NCT02423226 ↗ “modified folinic acid (leucovorin), fluorouracil, and oxaliplatin will be administered at a protocol-defined dose” NCT06835569 ↗ “Modified FOLFIRINOX (Folinic acid/Leucovorin, 5-Fluouracil, Irinotecan, Oxaliplatin) administered intravenously.” NCT04469556 ↗ “neoadjuvant chemotherapy (docetaxel, oxaliplatin and fluorouracil/leucovorin) plus avelumab previous to surgery.” NCT03979131 ↗ “5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer” NCT06887218 ↗ “Pazopanib With 5-Fluorouracil, Leucovorin and Oxaliplatin (FLO) as 1st-line Treatment in Advanced Gastric Cancer” NCT01503372 ↗ “Fluorouracil: 400 mg/m2 as a bolus injection given after a two-hour leucovorin infusion at a dose of 400 mg/m2.” NCT04625803 ↗ “Oxaliplatin 85 mg/m2, Leucovorin 400 mg/m2, Irinotecan 150 mg/m2, 5-Fluorouracil 2400 mg/m2 46-48 hour infusion” NCT04229004 ↗ “HAIC：administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks” NCT06867432 ↗ “Three-drug chemotherapy group, mFOLFIRINOX, including 5-fluorouracil, leucovorin, oxaliplatin and irinotecan.” NCT06867146 ↗ “oxaliplatin (85 mg/m2), leucovorin (400 mg/m2) and bolus 5-FU (400 mg/m2) and continuous IV 5-FU (2400 mg/m2)” NCT00625651 ↗ “5-fluorouracil 2,000 mg/m2 and Leucovorin 300mg/m2 24-hour infusion for day 1, day 8 and day 15 every 4 weeks” NCT02648425 ↗ “FOLFOX: Day1- Oxaliplatin 85mg/m2, Leucovorin 200mg/m2, 5-FU 400mg/m2 IV bolus -\> 2400mg/m2 46hrs continuous” NCT01269229 ↗ “Drug: FOLFOX Protocol (Oxaliplatin, fluorouracil, and leucovorin); Bevacizumab and Sintilimab for injection.” NCT05214339 ↗ “Hepatic intra-arterial infusion via the tumor feeding arteries of Oxaliplatin , fluorouracil, and leucovorin” NCT02856126 ↗ “Hepatic intra-arterial infusion via the tumor feeding arteries of Oxaliplatin , fluorouracil, and leucovorin” NCT03469479 ↗ “Participants received standard chemotherapy regimen (FOLFIRI) consisting of 5-FU, leucovorin and irinotecan.” NCT00339183 ↗ “Leucovorin 400 mg/m² IV infusion over 120 minutes, or 200 mg/m² levo-leucovorin if leucovorin is unavailable” NCT03343301 ↗ “* Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)” NCT02581462 ↗ “Leucovorin 200 mg/m2 plus 5-FU 400mg IV bolus, then continuous 22 hour 600 mg/m2 infusion on day 1 and 2 Q2W” NCT01023633 ↗ “Leucovorin: 400 mg/m2 IV over the course of 30 minutes (±5 minutes) on days 1 and 15 of every 4-week cycle.” NCT05851924 ↗ “Oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, infusinal 5-fluorouracil 2400 mg/m2 every 2 weeks, for 9 cycles” NCT06162650 ↗ “Three additional cycles of 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX4) consolidation chemotherapy” NCT05241574 ↗ “Leucovorin, 400 mg/m2, IV over 2 hours with irinotecan, administered on days 1 and 15 of each 28 day cycle” NCT02178709 ↗ “docetaxel 50 mg/m², oxaliplatin 85 mg/m², leucovorin 200 mg/m² and 5-FU 2600 mg/m², all i.v. on day 1 Q2W” NCT07059299 ↗ “Chemotherapy regimen of Oxaliplatin 85mg/m2 , Leucovorin 400 mg/m2 , Irinotecan 165mg/m2 , 5-Fluorouracil” NCT04380337 ↗ “oxaliplatin 85 mg/ m\^2 + leucovorin 400 mg/ m\^2 (or 200 mg/ m\^2 levo-leucovorin) as a 2-hr IV infusion” NCT00609622 ↗ “Day 2-6: leucovorin 200mg/m² IV infusion in D5W both given over 2 hours at the same time in separate bags” NCT03084809 ↗ “The EACH study assessed the efficacy of oxaliplatin, 5-fluorouracil, and leucovorin (the FOLFOX4 regimen)” PMID 25223462 ↗ Sep 2014 “FLOT (5-FU, leucovorin, oxaliplatin, and docetaxel) Chemotherapy will be administered as an IV infusion.” NCT07069712 ↗ “mFOLFIRINOX (oxaliplatin, leucovorin, irinotecan, 5-FU) will be administered IV at specified timepoints.” NCT05968326 ↗ “leucovorin 200 mg/m2 in 100 mL 0.9% NaCl solution, IVD (administered as 2-hour infusion) on days 1 and 2” NCT02813096 ↗ “leucovorin 400 mg/m2 2-hour infusions with the addition of irinotecan 150 mg/m2 as a 90 minute infusion” NCT04672005 ↗ “Oxaliplatin 85mg/m2, leucovorin 400mg/m2 ivgtt d1 and 5-FU 400 mg/m2 IV bolus d1，2400 mg/m2 CIV 46h, d1” NCT04416854 ↗ “Irinotecan165 mg/m2、Oxaliplatin85 mg/m2、Left-calcium leucovorin 200mg/㎡，Intravenous infusion，first day.” NCT03671252 ↗ “* Leucovorin - Administered at a starting dose of 400 mg/m2 over 2 hours on day 1 of each 14 day cycle” NCT03563248 ↗ “leucovorin 400 mg/m² racemate or 200 mg/m² levo-leucovorin administered as a 2-hour infusion on day 1” NCT01327612 ↗ “Chemotherapy regimen of nanoliposomal irinotecan, oxaliplatin, fluorouracil \[5-FU\], and leucovorin.” NCT06736717 ↗ “Standard chemotherapy regimen (5-fluorouracil, leucovorin, and oxaliplatin), after chemoradiotherapy” NCT07622017 ↗ “FOLFOX regimens combine oxaliplatin and leucovorin with bolus and infusional 5-fluorouracil (5-FU).” NCT01047293 ↗ “with intravenous leucovorin (20 mg/m2 BSA) and bolus 5-fluorouracil (400 mg/m2 BSA) every six weeks” NCT03246321 ↗ “FOLFIRI (leucovorin [folinic acid], fluorouracil, and irinotecan) plus cetuximab induction therapy” PMID 37721754 ↗ Sep 2023 “Oxaliplatin, leucovorin, bolus fluorouracil, and infusional fluorouracil 2400 mg/m² over 46 hours” NCT05476432 ↗ “Leucovorin day 1 every 14 days. Levoleucovorin may be substituted if leucovorin is not available.” NCT03904043 ↗ “Oxaliplatin, Leucovorin and 5-fluorouracil given as part of standard mFOLFOX chemotherapy regimen” NCT03720678 ↗ “mFOLFOX6: oxaliplatin 85 mg/m², leucovorin 400 mg/m², 5-fluorouracil 400 mg/m² IV bolus on Day 1” NCT07581626 ↗ “immediately followed by leucovorin at a dose of 400 mg/m2 given as a 2-hour intravenous infusion” NCT06384560 ↗ “RFA Combined With Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) for Recurrent HCC” NCT02426450 ↗ “Arm B will receive leucovorin, fluorouracil, and irinotecan every two weeks through an infusion” NCT05419479 ↗ “NALIRIFOX (liposomal irinotecan in combination with fluorouracil, leucovorin, and oxaliplatin)” NCT06816914 ↗ “HD-MTX 5g/m²in two doses (0.5g/m² in 0.5h and 4.5g/m² in 23.5h), days 15 and 29 (+ Leucovorin)” NCT02066220 ↗ “IV Onivyde® followed by IV leucovorin (LV), followed by IV fluorouracil (5-FU), every 2 weeks.” NCT02826486 ↗ “Leucovorin 200mg/M2 intravenous Oxaliplatin 85mg/ M2 intravenous Docetaxel 50mg/M2 intravenous” NCT04384601 ↗ “leucovorin at 200 mg/m2 (400 mg/m2 if using d,l-racemic mixture of leucovorin) by IV infusion” NCT01347645 ↗ “FOLFOX (leucovorin + 5-fluorouracil + oxaliplatin) given IV, on days 1 and 15 in 28 day cycle” NCT01632306 ↗ “Oxaliplatin 85 mg/m² and Leucovorin 400 mg/m² infused via arterial pump over 2 hours on day 1” NCT07024537 ↗ “5-fluorouracil oxaliplatin, leucovorin (levoleucovorin when locally preferred and available)” NCT05702229 ↗ “docetaxel 50 mg/m2, oxaliplatin 85 mg/m2, leucovorin 200 mg/m2 and 5-fluorouracil 2600 mg/m2” NCT04597294 ↗ “FOLFIRINOX is comprised of four drugs: Oxaliplatin, irinotecan, fluorouracil and leucovorin.” NCT01821729 ↗ “Folinic acid (leucovorin, LV) was preferred to folic acid as its bioavailability is higher.” PMID 20084109 ↗ Jan 2010 “administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries” NCT03722498 ↗ “hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil, leucovorin (FOLFOX) treatment” NCT06134193 ↗ “administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries” NCT03468231 ↗ “FOLFIRI is a chemotherapy regimen consisting of irinotecan, leucovorin, and 5-fluorouracil.” NCT03597581 ↗ “administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries” NCT03812770 ↗ “FOLFOX (oxaliplatin 85mg/m2, leucovorin 200mg/m2, 5-FU 400mg/m2, 5-FU continuous 1200mg/m2)” NCT03022734 ↗ “This therapy will be 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX).” NCT04683315 ↗ “hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment” NCT05524155 ↗ “hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment” NCT05029973 ↗ “typical FOLFOX4 (Cam-FOLFOX4 group; infusional 5-fluorouracil, leucovorin and oxaliplatin)” PMID 34309846 ↗ Sep 2021 “oxaliplatin 85mg/m2 + leucovorin 400mg/m2 + 5-fu 400mg/m2 + 5-fu 2400mg/m2 46h iv.drip Q3W” NCT07192185 ↗ “mFOLFOX6: 5-fluorouracil, leucovorin, and oxaliplatin will be administered as IV infusion.” NCT05111626 ↗ “FOL : folinic acid (leucovorin), a vitamin B derivative that enhances the effects of 5-FU” NCT05262452 ↗ “Fluorouracil (5-FU), leucovorin and oxaliplatin are considered traditional chemotherapies” NCT00116506 ↗ “Folinic Acid (Leucovorin): 400 mg/m2; 2-hour IV infusion simultaneously with oxaliplatin” NCT00831181 ↗ “Systemic chemotherapy consisting of Oxaliplatin + Leucovorin + 5- Fluorouracil (FOLFOX).” NCT00724503 ↗ “Day 1: Oxaliplatin 85mg/m2 IV + leucovorin 400mg/m2 IV + Fluorouracil (5-FU) 400mg/m2 IV” NCT03838406 ↗ “FOLFIRI (Leucovorin 200 mg/m2、5-FU 2800 mg/m2、Irinotecan 180 mg/m2) plus target therapy” NCT06826092 ↗ “FOLFIRI (irinotecan + fluorouracil \[5-FU\] + leucovorin) as intravenous (IV) infusion” NCT06106308 ↗ “Leucovorin 50mg every 6 hours starting 24 hours from the beginning of the MTX infusion” NCT01184885 ↗ “FOLFIRI (irinotecan + fluorouracil \[5-FU\] + leucovorin) as intravenous (IV) infusion” NCT05593328 ↗ “5-Flurouracil (5-FU), leucovorin, and irinotecan; the combination is known as FOLFIRI.” NCT01183494 ↗ “5-fluorouracil(FU) 2,400 mg/㎡ and leucovorin (LV) 100 mg/㎡ IV continuous over 46 hours” NCT00976768 ↗ “mFOLFOX6( Oxaliplatin + Leucovorin + fluorouracil) Oxaliplatin 85mg/m2 d1+CF 400mg/m2” NCT06329947 ↗ “mFOLFOX6 administered as a combination of oxaliplatin and leucovorin as IV infusions.” NCT05052801 ↗ “Oxaliplatin (65 mg/m\^2), Irinotecan (140 mg/m\^2), Leucovorin (400 mg/m\^2) on Day 1” NCT07312422 ↗ “IV administration of 85 mb/m(2) oxaliplatin and 400 mg/m(2) leucovorin over 120 mins” NCT01420874 ↗ “Chemotherapy consisting of irinotecan with infusional 5-fluorouracil and leucovorin.” NCT00411450 ↗ “Chemotherapy consisting of irinotecan with infusional 5-fluorouracil and leucovorin.” NCT00332163 ↗ “a chemotherapy regimen of oxaliplatin, 5-Fluorouracil (5-FU) and leucovorin (FOLFOX)” NCT01288339 ↗ “Combination of irinotecan, leucovorin, and 5-fluorouracil given via IV infusion Q2W.” NCT06252649 ↗ “5-FU 425 mg/m2 and Leucovorin 20 mg/m2 IV day 1, 2, 3, 4, and 5 of each 28 day cycle” NCT01411072 ↗ “modified FOLFOX-6 (oxaliplatin, leucovorin, and 5-fluorouracil) (nab-P/Gem-mFOLFOX)” PMID 38320486 ↗ Jan 2024 “6.1 FOLFOX Drug Dosage Timing Oxaliplatin 85 mg/m2 Day 1 Leucovorin 400 mg/m2 Day 1” NCT03528876 ↗ “Fluorouracil + leucovorin (calcium folinate) + irinotecan via intravenous infusion.” NCT07702032 ↗ “leucovorin (LV) (nal-IRI/5-FU/LV) combined with benmelstobart and anlotinib ± SBRT” NCT06662006 ↗ “Hepatic arterial infusion of 130 mg/m² oxaliplatin,leucovorin and 2400 mg/m² 5-FU” NCT04687163 ↗ “leucovorin (LV) and 5-fluorouracil (5-FU) were used as the main treatment options” NCT06415851 ↗ “NALIRIFOX is liposomal irinotecan with 5-fluorouracil/leucovorin and oxaliplatin.” NCT06483555 ↗ “Standard care chemotherapy regimen consisting of leucovorin, 5-FU and oxaliplatin” NCT00440310 ↗ “Oxaliplatin 85 mg/m2 IV, Leucovorin 400 mg/m2 IV and 5-FU 400 mg/m2 IV infusions” NCT00591123 ↗ “Leucovorin 400 mg/m2 IV over 30 minutes after completion of liposomal irinotecan” NCT03861702 ↗ “intravenous oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil 400 mg/m2” NCT06791512 ↗ “Leucovorin 400 mg/m2 IV infusion to match duration of irinotecan infusion, day 1” NCT03031444 ↗ “FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF” NCT00001338 ↗ “Systemic mFOLFOX6: 5-FU(2400mg/m²), Oxaliplatin(100mg/m²), Leucovorin(100mg/m²)” NCT03618758 ↗ “2000 mg/m2, IV 46-hour infusion of 5-Fluorouracil + 400 mg/m2, IV of Leucovorin” NCT03366155 ↗ “oral fluorouracil-uracil plus oral leucovorin calcium twice a day on days 1-21” NCT00009815 ↗ “irinotecan \[130 mg per square meter\], leucovorin \[200 mg per square meter\]” NCT06149689 ↗ “standard fluorouracil, leucovorin, and oxaliplatin (FOLFOX)-based chemotherapy” PMID 26903575 ↗ Feb 2016 “a 400 mg/m² leucovorin intra venous infusion in 250 ml dextrose 5% for 120 min” NCT05316818 ↗ “concurrent with leucovorin 400 mg/m2 (or levoleucovorin 200 mg/m2) IV infusion” NCT06509880 ↗ “infusions will consist of the drugs * 5-Fluorouracil * Irinotecan * Leucovorin” NCT03803553 ↗ “BOLD-100 +/- Folinic acid (leucovorin), Fluorouracil (5-FU), and Oxaliplatin.” NCT04421820 ↗ “irinotecan 180mg/m2, leucovorin 400 mg/m2, 5FU 400mg/m2 bolus, 2400 mg/m2 inf” NCT00479583 ↗ “Chemotherapy regimen of leucovorin, fluorouracil, irinotecan, and oxaliplatin” NCT03899636 ↗ “neoadjuvant mFOLFIRINOX (5-Fluorouracil, oxaliplatin, leucovorin, irinotecan)” NCT07671339 ↗ “folinic acid (leucovorin), a vitamin B derivative with multiple applications” NCT06047379 ↗ “Chemotherapy regimen of oxaliplatin, 5-fluorouracil \[5-FU\], and leucovorin” NCT03954704 ↗ “modified leucovorin, fluorouracil, irinotecan, and oxaliplatin [mFOLFIRINOX]” PMID 40184561 ↗ Apr 2025 “Drug: SLOG chemotherapy S-1, leucovorin, oxaliplatin, and gemcitabine (SLOG)” NCT06730009 ↗ “leucovorin 400mg/m2 given as 2-hour IV infusion with addition of irinotecan” NCT03690323 ↗ “Leucovorin 400 mg/m\^2 administered intravenously (Day 1 of FOLFOX therapy)” NCT05394740 ↗ “folinic acid (leucovorin), fluorouracil (5-FU), and oxaliplatin (mFOLFOX6)” NCT02102022 ↗ “followed by leucovorin 400 mg/m² by arterial infusion over 1 hour on Day 1” NCT07543510 ↗ “Oxaliplatin (Eloxatin), 5FU (5-Fluorouracil) and Leucovorin (Folinic Acid)” NCT00580073 ↗ “Leucovorin followed immediately by 50 mg/m2 iv every 6hrs for three doses,” NCT00844298 ↗ “irinotecan (180mg/m2), leucovorin 400 mg/m2 ± 5-FU (400 mg/m2) IV infusion” NCT07446322 ↗ “Oral tegafur/uracil 300 mg/m2/day plus leucovorin 90 mg/day on days 1 - 14” NCT03161548 ↗ “Leucovorin 400 mg/m² (or Calcium Folinate 200 mg/m²), IV, over 120 min, D1” NCT06959693 ↗ “5-Fluorouracil 380 mg/m2, leucovorin 20 mg/m2 on D1-5 q 4 weeks X 4 cycles” NCT00807911 ↗ “leucovorin (400 mg/m2) as a 120-min intravenous infusion on days 1 and 15” PMID 28397697 ↗ Feb 2017 “Methotrexate at D1 (24H infusion, alkaline hydration, leucovorin rescue):” NCT03599960 ↗ “or leucovorin \[dl-leucovorin\] 400 mg/m\^2 i.v. infusion over 90 minutes” NCT01085331 ↗ “Calcium Folinate IV over 2h on Day 1(Leucovorin 200mg/m2 or CF 400 mg/m2)” NCT02251977 ↗ “Folinic acid 400 mg/m2 (or Leucovorin 200 mg/m²) as a 2-hour IV infusion” NCT07616362 ↗ “Eloxatin (Oxaliplatin) + Leucovorin (Folinic acid) + 5-FU (Fluorouracil)” NCT02574663 ↗ “Chemotherapy with Docetaxel, Oxaliplatin, and 5-Fluorouracil/ Leucovorin” NCT04028167 ↗ “calcium leucovorin: 400 mg/m2, 30±10min intravenously, D1, every 2 weeks” NCT06387810 ↗ “Leucovorin IV over 2 hours on Day 1(l-LV 200 mg/m2 or dl-LV 400 mg/m2 );” NCT02023593 ↗ “FOLFIRINOX, which includes 5FU, Leucovorin, Irinotecan, and Oxaliplatin.” NCT04931420 ↗ “Folinic Acid (Leucovorin)\* 400 mg/m2 IV in 250 ml D5W over 120 minutes” NCT01274962 ↗ “Hepatic arterial infusion of oxaliplatin,leucovorin and 2400 mg/m² 5-FU” NCT04667351 ↗ “docetaxel, oxaliplatin, fluorouracil, and leucovorin (the FLOT regimen)” NCT06411171 ↗ “Drug: Leucovorin Dose: 400 mg/m2 Dose Frequency: Q2W Route: IV infusion” NCT03488667 ↗ “Cytoxan,Mesna,Adriamycin,Vincristine,Methotrexate,Leucovorin,Cytarabine” NCT00774332 ↗ “Leucovorin 400 mg/m2 IV 2 hours - given with irinotecan without mixing.” NCT00101686 ↗ “Hepatic Arterial Infusion of Oxaliplatin Plus Fluorouracil/Leucovorin” NCT05821361 ↗ “mFOLFIRINOX consists of oxaliplatin, irinotecan, leucovorin and 5-FU.” NCT02839343 ↗ “HD-MTX: High-dose methotrexate with leucovorin rescue in cycle 4,6,8.” NCT07493161 ↗ “Drug: Leucovorin 200mg/m2 administered IV on Days 1 of a 21 day cycle” NCT05412589 ↗ “metformin 850mg PO BID plus 5FU 425mg/m2 + leucovorin 50mg IV weekly” NCT01941953 ↗ “FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin)” PMID 32681477 ↗ Jul 2020 “* Day 1: oxaliplatin 85mg/m2 + irinotecan 150mg/m2 + leucovorin 50mg” NCT04089150 ↗ “L-VAMP (leucovorin, vincristine, aracytin, methotrexate, prednisone)” NCT04475731 ↗ “Folinic acid (leucovorin) 400 mg/m² is given intravenously on day 1” NCT06490536 ↗ “leucovorin (400 mg/m\^2) administered as a 2-hour infusion on Day 1” NCT02510118 ↗ “Leucovorin: 400 mg/m² via 120-minute intravenous infusion on Day 1.” NCT07176182 ↗ “5-fluorouracil, leucovorin and irinotecan (FOLFIRI) and bevacizumab” PMID 31101691 ↗ May 2019 “leucovorin (400 mg/m\^2) administered as a 2-hour infusion on Day 1” NCT00819780 ↗ “Leucovorin (LV) 400 mg/m², intravenous infusion over 2 hours, Day 1” NCT07604909 ↗ “leucovorin (400 mg/m\^2) administered as a 2-hour infusion on Day 1” NCT02590367 ↗ “Leucovorin (folinic acid) solution for infusion (IV administration)” NCT06967987 ↗ “Leucovorin: 400 mg/m², intravenous infusion over 2 hours, on day 1” NCT06603376 ↗ “Leucovorin at 400 mg/m2 was administered intravenously for 2 hours” NCT02503150 ↗ “HDFL (5-FU 2,000 mg/m2 and leucovorin 300 mg/m2), day 1 and day 8.” NCT00275951 ↗ “Systemic Chemotherapy (Oxaliplatin#5- fluorouracil and leucovorin)” NCT04682249 ↗ “Leucovorin: 400 mg / m2 IV over 15 minutes on day 1 of each cycle.” NCT04595266 ↗ “Leucovorin - bolus 400mg/m² following the oxaliplatin/FA infusions” NCT02017704 ↗ “Leucovorin (LV) 400 mg/m2 iv administered over a period of 2 hours” NCT01640444 ↗ “Leucovorin 200 mg/m2 IV(in vein) from hour 0 to 2 on days 1 and 2” NCT02534337 ↗ “Leucovorin, 400 mg/m2 IV every two weeks over 90 minutes on Day 1” NCT05825066 ↗ “Systemic Chemotherapy (Oxaliplatin#5-fluorouracil and leucovorin)” NCT04769908 ↗ “FOLFIRI (Irinotecan, leucovorin, 5FU I.V.bolus and 5FU I.V. c.i.)” NCT01853813 ↗ “the chemotherapy drugs oxaliplatin,leucovorin and 5-fluorouracil” NCT02909478 ↗ “On each treatment day you will get Oxaliplatin, 5-FU,Leucovorin.” NCT00826800 ↗ “Nimotuzumab plus Irinotecan/5FU/leucovorin as 2nd line treatment” NCT01486992 ↗ “leucovorin 400 mg/m\^2 or levoleucovorin 200 mg/m\^2 IV on Day 1” NCT02563002 ↗ “leucovorin 200 mg/m2 intravenous infusion on day 1 every 2 weeks” NCT06253650 ↗ “Modified Folfox; Oxaliplatin, 5-fluorouracil (5-FU), leucovorin” NCT05116891 ↗ “Leucovorin: intravenous, 400 mg/m2, over 2 hrs, once per cycle.” NCT01383538 ↗ “Leucovorin 200mg/m2 administered IV on Days 1 of a 21 day cycle” NCT06172205 ↗ “Leucovorin**: 400 mg/m2 IV over 2 hours on Day 1, followed by,” NCT05462496 ↗ “Leucovorin: 400mg/m2 IV over 2hrs with Irinotecan-14 day cycle” NCT05070104 ↗ “FOLFOX-HAIC: Oxaliplatin 130 or 85 mg/m2; leucovorin 200 mg/m2” NCT06143579 ↗ “Leucovorin/folinic acid- 400 mg/m2, IV over 90 minutes, day 1” NCT05926206 ↗ “Oxaliplatin 130 mg/m² d1 concurrent with Leucovorin 400 mg/m²” NCT04516681 ↗ “leucovorin (LV) 400 mg/m² intravenously over 2 hours on Day 1” NCT07683403 ↗ “leucovorin racemate 200 mg/m2 (or 100 mg/m2 l-LV) IV infusion” NCT00101894 ↗ “FOLFOX (oxaliplatin, 5FU, leucovorin) will follow IP therapy.” NCT00352755 ↗ “5- Fluorouracil (FU)/Leucovorin (LV), day 1 and 2, as follow:” NCT01640405 ↗ “EMB-01 + 5-Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI)” NCT07649655 ↗ “FOLFIRI regimen (irinotecan, leucovorin, and 5-fluorouracil” NCT01133990 ↗ “After IV administration of Leucovorin 400 mg/m2 for 2 hours” NCT05257993 ↗ “LVFU2 (5FU-Leucovorin) or FOLFIRI (5FU-Irinotecan) regimens” NCT03253133 ↗ “concurrent oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 IV” NCT03130790 ↗ “Leucovorin 400mg/m2 intravenously over 90 minutes on day 1.” NCT01661088 ↗ “mFOLFIRINOX: - Oxaliplatin; Leucovorin; Irinotecan and 5-FU” NCT05354817 ↗ “Leucovorin at a dose of 400 mg/m2 iv over two hours (day 1)” NCT03647969 ↗ “FOLFOX (fluorouracil, leucovorin, oxaliplatin) chemotherapy” NCT03781323 ↗ “Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days” NCT02080221 ↗ “mFOLFIRINOX:Fluorouracil+leucovorin+Irinotecan+Oxaliplatin” NCT06913218 ↗ “Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days” NCT02578732 ↗ “oral S-1/leucovorin [35 mg/m2 and 30 mg bid from D1 to D7]” PMID 38902994 ↗ Oct 2024 “Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days” NCT02022033 ↗ “Leucovorin: 400 mg/m² IV infusion from Hour 2-3 on Day 1.” NCT07328009 ↗ “Leucovorin (LV): 400 mg/m², infused over 2 hours on Day 1” NCT07646717 ↗ “leucovorin 400 mg/m2, administered as 2-hour iv infusion” NCT04431258 ↗ “oxaliplatin IV, irinotecan IV, leucovorin IV and 5-FU IV” NCT05083247 ↗ “* Leucovorin 400mg/m2 IV (concurrently with oxaliplatin)” NCT05534087 ↗ “5FU, leucovorin, oxaliplatin, irinotecan and bevacizumab” NCT03401294 ↗ “leucovorin 400 mg/m\^2 (90-minute infusion ± 30 minutes)” NCT02305758 ↗ “Leucovorin(LV) 200 mg/m2 Day 1 and 15 of a 28-day cycle” NCT06389760 ↗ “Leucovorin (l-LV) 200mg/m2 IV over 2 hours on Day 1, 15” NCT02102789 ↗ “Includes oxaliplatin, irinotecan, leucovorin, and 5-FU.” NCT06648434 ↗ “together with leucovorin 400 mg/m2 i.v. in 120 minutes” NCT02162563 ↗ “5-Fluorouracil (5FU), leucovorin (LV), and irrinotecan” NCT01434069 ↗ “5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6)” NCT04418895 ↗ “combination of Fluorouracil, leucovorin and irinotecan” NCT02033551 ↗ “leucovorin \[10 mg/mL concentration; administered IV\]” NCT03798626 ↗ “leucovorin 400 mg/m\^2 bolus IV over 2 hours on day 1” NCT01515787 ↗ “mFOLFOX6 (5-Fluorouracil, Leucovorin and Oxaliplatin)” NCT03110926 ↗ “Paclitaxel plus Oxaliplatin plus Leucovorin plus 5-FU” NCT02845908 ↗ “mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil)” NCT07228832 ↗ “Leucovorin 400 (or levoleucovorin 200) mg/m2 IV day 1” NCT05179889 ↗ “FOLFOX-4 (oxaliplatin, leucovorin and 5-fluorouracil)” NCT00349336 ↗ “Paclitaxel plus Oxaliplatin plus Leucovorin plus 5-FU” NCT04155671 ↗ “Leucovorin via IV, predetermined dosage per protocol” NCT04656041 ↗ “5fu/ leucovorin / oxaliplatin / liposomal irinotecan” NCT07163273 ↗ “mFOLFOX6: oxaliplatin 85 mg/m2, leucovorin 400 mg/m2” NCT06890624 ↗ “48-hour intravenous infusion of 5-FU and leucovorin” NCT00154791 ↗ “* Leucovorin 400 mg/m2 IV over 2 hrs on Day 1 and 2” NCT01923987 ↗ “Leucovorin 100mg/m2 in N/S 100ml IV drip 2hrs on D1” NCT02284529 ↗ “leucovorin calcium IV over 2 hours on days 1 and 15” NCT01417494 ↗ “Leucovorin 400 mg/m\^2 IV infusion over 120 minutes” NCT01571284 ↗ “5-fluorouracil, oxaliplatin, Irinotecan, leucovorin” NCT04292743 ↗ “FOLFOX: Oxaliplatin, leucovorin, and 5-fluorouracil” NCT00911170 ↗ “Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1” NCT04224402 ↗ “Leucovorin: 200 mg/m2 via 2-hour IV infusion, day 1” NCT02591667 ↗ “Leucovorin (folinic acid) 400 mg/m\\(\^2\\), IV, d1” NCT06650332 ↗ “Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1” NCT02028806 ↗ “Leucovorin will be administered 400 mg/m2 biweekly.” NCT03391934 ↗ “Fluorouracil/Leucovorin, Oxaliplatin (5-FU/LV, OX)” NCT07074353 ↗ “5-FU, Leucovorin, and Oxaliplatin (FOLFOX regimen)” NCT02843191 ↗ “Leucovorin (LV), 400 mg/m² IV over 2 hours (Day 1)” NCT07021950 ↗ “Leucovorin 400 mg/m² IV infusion over 120 minutes” NCT03694522 ↗ “D1 Leucovorin 100 mg/m2 + D5W 500mL MIV over 2hrs” NCT00313872 ↗ “FOLFOX4 (leucovorin + fluorouracil + oxaliplatin)” NCT02069041 ↗ “Leucovorin: 200 mg/m2 iv on day1,2 every 14 days.” NCT02439385 ↗ “* leucovorin 400 mg/m2 IV over 2 hours, and then” NCT05848739 ↗ “FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)” NCT07472868 ↗ “Folinic acid (leucovorin) 400 mg/m2 IV infusion” NCT04145193 ↗ “leucovorin (20 mg/m2, IV bolus on D1-3, D29-31)” NCT02167321 ↗ “Leucovorin as a 100 mg/m2 infusion over 2 hours” NCT01030042 ↗ “Irinotecan/5FU/leucovorin as 2nd line treatment” NCT01044420 ↗ “5-fluorouracil (5-FU), leucovorin. oxaliplatin” NCT01322815 ↗ “Leucovorin 400 mg/m2 over a 2 hour IV infusion” NCT01488552 ↗ “Leucovorin + Fluorouracil (5-FU) + Oxaliplatin” NCT00599924 ↗ “oxaliplatin , leucovorin and 5-fluorouracil IV” NCT00381706 ↗ “HAIC: Oxaliplatin plus Fluorouracil/Leucovorin” NCT05864755 ↗ “Leucovorin 50 mg/m2 iv every 6hr for 3 doses,” NCT01429610 ↗ “Leucovorin (LV) levogyre form (LLV) 200 mg/m²” NCT03982121 ↗ “Leucovorin 400mg/m\^2 IV over 2 hours, Day 1” NCT02529774 ↗ “Leucovorin 200 mg/m2, IV infusion, q 2 weeks” NCT00735241 ↗ “leucovorin 400 mg/m² iv continue for 2 hours” NCT05201430 ↗ “Leucovorin (LV): 400 mg/m² IV infusion on D1” NCT07047560 ↗ “Oxaliplatin IV associated with LeucovorinIV” NCT01964287 ↗ “leucovorin 400 mg/m2 IV over 2 hrs on Day 1” NCT00752570 ↗ “Leucovorin 400mg/m2 + 5DW 500ml over 2hr D1” NCT01748851 ↗ “leucovorin 200 mg/m2/day on Day 1 and Day 2” NCT00890305 ↗ “leucovorin, 200 mg/m2/day on day 1\~5, i.v.” NCT01197118 ↗ “Leucovorin(l-form) 200 mg/m2 iv on day 1,2” NCT01543412 ↗ “Oxaliplatin , fluorouracil, and leucovorin” NCT02981498 ↗ “Leucovorin 400mg/m2 IV over 2 hours, day 1” NCT02202928 ↗ “Oxaliplatin , fluorouracil, and leucovorin” NCT04962958 ↗ “Leucovorin 400 mg/m2 IV over 2 hours Day 1” NCT02358863 ↗ “Leucovorin 400mg/m2 IV over 2 hours, day 1” NCT02215837 ↗ “Leucovorin(l-LV) 400 mg/m2 IV over 2 hours” NCT06153368 ↗ “Leucovorin 400mg/m2 IV Day 1 of each cycle” NCT04130854 ↗ “Oxaliplatin , fluorouracil, and leucovorin” NCT03812783 ↗ “Oxaliplatin , fluorouracil, and leucovorin” NCT03803254 ↗ “5-Fluorouracil, Leucovorin and Oxaliplatin” NCT00502567 ↗ “Leucovorin, fluorouracil, and oxaliplatin” NCT06253611 ↗ “2. Leucovorin, 400 mg/m2, IV over 2 hours” NCT03603834 ↗ “Leucovorin : 400mg/m2 IV over 2-hr, day 1” NCT05103020 ↗ “Leucovorin (LV) - Starting dose 400 mg/m2” NCT02726334 ↗ “Leucovorin 400mg/m2 day 1 (every 2 weeks)” NCT06275958 ↗ “leucovorin 400 mg/m2 as a 2-hour infusion” NCT03415763 ↗ “5-fluorouracil + leucovorin + irinotecan” NCT01605344 ↗ “Leucovorin 400 mg/m2 over 2 hours, day 1” NCT03193814 ↗ “* Leucovorin 400 mg/m2 IV short infusion” NCT04769414 ↗ “Leucovorin 100 mg/sqm on day 1 and day 2” NCT01219920 ↗ “400 mg/m2 BSA of leucovorin, IV on day 1” NCT02758951 ↗ “Leucovorin, 5-fluorouracil, Oxaliplatin” NCT05919264 ↗ “Oxaliplatin + leucovorin + fluorouracil” NCT06123455 ↗ “FOLFIRI (5-FU, irinotecan, leucovorin).” NCT02482441 ↗ “Oxaliplatin, leucovorin, 5-fluorouracil” NCT00613080 ↗ “5-FU/leucovorin (2400 mg/m2, 400 mg/m2)” NCT05363007 ↗ “Oxaliplatin + leucovorin + fluorouracil” NCT03662659 ↗ “i.v. infusion of leucovorin\* 400 mg/m2” NCT03081143 ↗ “leucovorin 200 mg/m² + 5-FU 2800 mg/m²” NCT02942563 ↗ “Leucovorin 400 mg/m\^2 IV over 2 hours” NCT02405585 ↗ “Leucovorin 200 mg/m² IV infusion on D1” NCT04736485 ↗ “Leucovorin 400 mg/m2 IV over two hours” NCT01523457 ↗ “Leucovorin: 400 mg/m2 D1 every 2 weeks” NCT02486601 ↗ “Leucovorin 400n mg/m² for over 2 hours” NCT02128100 ↗ “Leucovorin (LV): 400 mg/m² IV on Day 1” NCT06521866 ↗ “Leucovorin 200 mg/m2 2- hour I.V, D1,2” NCT02311439 ↗ “Leucovorin 400 mg per square meter IV” NCT06048484 ↗ “Leucovorin 400 mg/m\^2 IV followed by” NCT02375672 ↗ “leucovorin 200 mg/m2 from hour 3 to 5” NCT03164382 ↗ “fluorouracil, leucovorin, oxaliplatin” NCT06385925 ↗ “5-fluorouracil (5-FU)/leucovorin (LV)” NCT02448810 ↗ “Leucovorin 200mg/m2 IV 2h, 1, 2 days” NCT05721872 ↗ “Leucovorin 400 mg/m2 IV over 2 hours” NCT00673673 ↗ “leucovorin : 400mg/m2, I.V., D1, Q2W” NCT06871527 ↗ “* Leucovorin 400 mg/m², followed by” NCT02969681 ↗ “Leucovorin 400 mg/m² over 2-3 hours” NCT07618546 ↗ “Leucovorin 400mg/m2 IV over 2 hours” NCT04452461 ↗ “leucovorin (mg/m2) IV, over 2 hours” NCT00200200 ↗ “intravenous leucovorin [200 mg/m2]” PMID 36328033 ↗ Oct 2022 “leucovorin 400mg/m2 IV infusion D1” NCT06151262 ↗ “5-FU/LV: leucovorin 200 mg/m2 i.v.” NCT06731803 ↗ “leucovorin: 400 mg/m2 iv gtt , D1” NCT01322178 ↗ “leucovorin 400 mg/m2 over 2 hours” NCT04611724 ↗ “Leucovorin： 400 mg/m2 IV d1, q2w;” NCT05074966 ↗ “Leucovorin：400mg/m2，IV，d1，d15，d29” NCT06452602 ↗ “Leucovorin 350 mg IV over 2 hours” NCT00463840 ↗ “leucovorin, 200 mg/m\^2 on Days 1” NCT04233151 ↗ “3. leucovorin: 400 mg/m2, d1, q2w” NCT06643793 ↗ “Leucovorin 400 mg/m², followed by” NCT03015675 ↗ “leucovorin 200 mg/m2 over 2 hours” NCT06978062 ↗ “2. Leucovorin-400 mg/m2 IV Day 1” NCT03291899 ↗ “5-FU, leucovorin and oxaliplatin” NCT03692429 ↗ “Leucovorin 20mg/m2 IVF for 1hour” NCT01283204 ↗ “5-FU, leucovorin and oxaliplatin” NCT04991948 ↗ “leucovorin 400 mg/m² IV over 2 h” NCT07328087 ↗ “oxaliplatin,leucovorin, and 5-FU” NCT05171166 ↗ “leucovorin 400 mg/m2 IV on Day 1” NCT06719362 ↗ “Leucovorin 200 mg/m2 IV on Day 1” NCT05733689 ↗ “leucovorin 200 mg/m² IV infusion” NCT03377842 ↗ “leucovorin 400mg/m2 ivgtt 2h d1” NCT03939962 ↗ “Leucovorin 400 mg/m2 IV over 2h” NCT03254394 ↗ “IV leucovorin 400 mg/m2 over 2h” NCT05194878 ↗ “IV leucovorin 400 mg/m2 over 2h” NCT02572141 ↗ “oxaliplatin,leucovorin and 5-FU” NCT03048123 ↗ “400 mg/m2 BSA of leucovorin IV” NCT04389086 ↗ “Calcium folinate (leucovorin)” NCT06094140 ↗ “Oxaliplatin, Leucovorin, 5-FU” NCT07543471 ↗ “leucovorin 400 mg/m² IV Day 1” NCT07053150 ↗ “Leucovorin: 400mg/m2, iv, D1” NCT06888037 ↗ “MTX: Methotrexate,Leucovorin” NCT01083342 ↗ “leucovorin 300mg/m2, 2h, day” NCT07012798 ↗ “Leucovorin: 200mg/m2, Day 1” NCT05617430 ↗ “Leucovorin: 200mg/m2, Day 1” NCT06244225 ↗ “Leucovorin: 400 mg IV Day 1” NCT00881504 ↗ “leucovorin 400mg/m2 IV day ” NCT05353582 ↗ “Leucovorin 200 mg/m² d1+d2” NCT00479752 ↗ “leucovorin 400 mg/m² day 1” NCT04423965 ↗ “Leucovorin 400 mg/m2,ivgtt” NCT01658033 ↗ “Leucovorin IV 400 mg/m2 D1” NCT02749136 ↗ “day1: Leucovorin 200mg/m2” NCT01460589 ↗ “Leucovorin (Folinic Acid)” NCT01749956 ↗ “Leucovorin (Folinic Acid)” NCT01260415 ↗ “leucovorin (400 mg/m2 IV)” NCT05986227 ↗ “Leucovorin (400 mg/m\^2)” NCT01595321 ↗ “leucovorin 200 mg/m², d1” NCT04908566 ↗ “Leucovorin: 400 mg/m2 IV” NCT01571024 ↗ “Irinotecan Leucovorin FU” NCT05605509 ↗ “* Leucovorin (400mg/ m2)” NCT01688336 ↗ “leucovorin 400 mg/m2 IV” NCT03483038 ↗ “Leucovorin 400 mg/m2 d1” NCT01310478 ↗ “leucovorin 400mg/m2 D1” NCT05066802 ↗ “Leucovorin 400mg/m2 IV” NCT05174169 ↗ “400 mg/m\^2 leucovorin” NCT06936527 ↗ “400 mg/m\^2 leucovorin” NCT03829410 ↗ “- Leucovorin 200 mg/m²” NCT02128243 ↗ “leucovorin, 400 mg/m2” NCT06919848 ↗ “leucovorin: 400 mg/m2” NCT05087992 ↗ “Leucovorin 200 mg/m².” NCT06501989 ↗ “Leucovorin 400 mg/m²” NCT06813976 ↗ “leucovorin 400 mg/m²” NCT04170530 ↗ “leucovorin (LCV)” NCT05378867 ↗ “Drug: Leucovorin” NCT01014767 ↗ “Drug: Leucovorin” NCT03872947 ↗ “Drug: Leucovorin” NCT07028424 ↗ “leucovorin (LV)” PMID 19457245 ↗ May 2009 “plus leucovorin” NCT05864105 ↗ “leucovorin” NCT05171166 ↗ “Leucovorin” NCT02063529 ↗ “Leucovorin” NCT07532902 ↗ “leucovorin” NCT00832299 ↗ “Leucovorin” NCT03117972 ↗ “Leucovorin” NCT02887313 ↗ “Leucovorin” NCT03303495 ↗ “Leucovorin” NCT02128425 ↗ “Leucovorin” NCT04215731 ↗ “Leucovorin” NCT04553692 ↗ “Leucovorin” NCT04169347 ↗ “leucovorin” NCT01726582 ↗ |
| Known as | 5-formyl tetrahydrofolic acid | “folinic acid (also known as: 5-formyl tetrahydrofolic acid and leucovorin) intravenous infusion, and 5-FU (also known as; fluorouracil) intravenous bolus/intravenous infusion” NCT05004350 ↗ |
| Known as | 5-formyltetrahydrofolate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00877227 ↗ |
| Known as | Ca-folinate | “Leucovorin (Ca-folinate) (200 mg/m2)” NCT02578368 ↗ |
| Known as | calcium folinate | “Patients were randomly assigned (1:1; block size of three), without stratification, to receive FOLFIRI (irinotecan 180 mg/m2, calcium folinate 400 mg/m2 or levofolinate 200...” PMID 36739879 ↗ Feb 202382“A Randomised Phase II Study Investigating Two Doses of Arfolitixorin Compared to Calciumfolinate Together With 5- Fluorouracil on TS Inhibition in Tumour and Adjacent Hepatic...” NCT04126655 ↗ “The treatment option for the standard second-line FOLFIRI + bevacizumab therapy group is bevacizumab 5 mg/kg IV Drip Q2W, irinotecan 180 mg/m2 IV Drip Q2W, calcium folinate 400...” NCT05768503 ↗ “This is a randomized phase II multicenter controlled study of oxaliplatin, calcium folinate, and 5-fluorouracil (mFOLFOX7) as neoadjuvant chemotherapy for resectable advanced...” NCT00591045 ↗ “The FOLFOXIRI regimen includes irinotecan 165mg/m2, oxaliplatin 85mg/m2, calcium folinate 200mg/m2 on day 1, followed by continuous intravenous infusion of 5-FU 2400mg/m2/day...” NCT06099951 ↗ “folinic acid (also called leucovorin, calcium folinate or FA) fluorouracil (also called 5FU) irinotecan given per institutional standard (intravenously day 1 and day 15 of 28 day cycle)” NCT04587128 ↗ “Folinic acid calcium salt (calcium folinate) is the bioactive metabolite of folic acid that does not require reduction by dihydrofolate reductase (DHFR).” NCT04723134 ↗ “Bevacizumab 5mg/kg d1 Oxaliplatin 85mg/m2 d1 Calcium Folinate 400mg/m2 d1 5-fluorouridine 400mg/m2 d1 5-fluorouridine 2400mg/m2 46h q2w, 6 cycles” NCT05111860 ↗ “Docetaxel 50mg/m2, ivgtt, d1; Oxaliplatin 85 mg/m2, ivgtt, d1; Calcium folinate 200mg/m2, ivgtt, d1; 5-fluorouracil 2600mg/m2, 24h civ, d1,” NCT05610332 ↗ “50 mg/m² docetaxel, 85 mg/m² oxaliplatin, 200 mg/m² calcium folinate and 2600 mg/m² fluorouracil as 24 h-infusion, 2 cycles” NCT05713838 ↗ “combined with fluorouracil / calcium folinate or Capecitabine or S1; combine or not combine with Bevacizumab or Cetuximab” NCT03567629 ↗ “Calcium folinate: give irinotecan at a dose of 400mg/m2 by intravenous drip in conjunction with irinotecan infusion” NCT06269445 ↗ “Recombinant anti-EGFR humanized monoclonal antibody in combination with Oxaliplatin, Calcium Folinate and 5-FU.” NCT03577704 ↗ “calcium folinate 400 mg/m\^2 + irinotecan 135 mg/m\^2 + oxaliplatin 68 mg/m\^2 (day 1, 15, a total of 28 days).” NCT03633734 ↗ “Oral adjuvant chemotherapy, tegafon (400 mg, QID) and Calcium Folinate Tablets (30 mg, QID).” NCT03529279 ↗ “Calcium Folinate (LV): 400 mg/m², Day 1, intravenous infusion (ivgtt), every 3 weeks (Q3W).” NCT06993025 ↗ “HAIC (FOLFOX: oxaliplatin 85mg/m2, 5- fluorouracil 2500mg/m2, calcium folinate 400mg/m2)” NCT05753163 ↗ “Calcium folinate 400mg/m2 intravenous infusion (over 2 hours or more), on the first day” NCT06363552 ↗ “Fluorouracil + leucovorin (calcium folinate) + irinotecan via intravenous infusion.” NCT07702032 ↗ “Calcium folinate (folinic acid) 20 mg/m2/day intravenously on days 1-4 and 33-35.” NCT06758830 ↗ “FOLFOX regimen: Oxaliplatin 85mg/m2 on day 1; Calcium folinate 400mg/m2 on day 1” NCT03485027 ↗ “oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid)” NCT02658214 ↗ “Drug: calcium Folinate 400 mg/sqm by IV, day1.Component of mFOLFOX6 or FOLFORI.” NCT05652894 ↗ “Ongericimab, Toripalimab, Bevacizumab, Oxaliplatin, Calcium folinate, 5-FU, Q2W” NCT07106034 ↗ “Mesna was given with ifosfamide, calcium-folinate rescue after methotrexate.” NCT00517894 ↗ “Leucovorin 400 mg/m² (or Calcium Folinate 200 mg/m²), IV, over 120 min, D1” NCT06959693 ↗ “Gemcitabine+Capecitabine or Oxaliplatin+lrinotecan+Calcium folinate+5-FU” NCT07114666 ↗ “Calcium folinate: 400 mg/m² intravenous infusion over 2 hours, on day 1;” NCT07469956 ↗ “Calcium Folinate 400 mg/m², intravenous infusion over 2 hours, Day 1;” NCT07229846 ↗ “Calcium folinate 400mg/m2 intravenous infusion for 2 hours, day 1” NCT06239870 ↗ “Drugs:FOLFOX regimen: oxaliplatin, calcium folinate, and 5-FU.” NCT05833126 ↗ “FOLFIRI-3 = irinotecan + calcium folinate + 5-fluorouracil” NCT03288987 ↗ “Calcium folinate 400mg/m2 ivgtt over 2 hours on day 1” NCT06242418 ↗ “Calcium folinate (400mg/m2), intravenous infusion, D1” NCT06154538 ↗ “oxaliplatin + calcium folinate + fluorouracil regimen” NCT04198051 ↗ “Calcium folinate,400mg/m2,intravenous titration，Q2W” NCT05684211 ↗ “oxaliplatin+lrinotecan+calcium folinate+5-FU” NCT07594964 ↗ “Drug Calcium Folinate 400 mg/m2（D1,iv）” NCT04835142 ↗ “Drug: Leucovorin (Calcium Folinate)” NCT07621718 ↗ “Drug: Leucovorin (Calcium Folinate)” NCT02720068 ↗ “Calciumfolinate: 400 mg/m² on day 1” NCT00349076 ↗ “calcium folinate 200mg” NCT06402708 ↗ “Calcium Folinate” NCT07262567 ↗ “Calcium Folinate” NCT07262567 ↗ |
| Known as | calcium leucovorin | “5-fluorouracil(5-FU), calcium leucovorin(LV), and bevacizumab” NCT06643793 ↗4“calcium leucovorin (20 mg/m\^2) IV bolus, on Days 1, 8, 15” NCT02620800 ↗ “Oxaliplatin, Fluorouracil, calcium leucovorin” NCT05590117 ↗ “calcium leucovorin:200mg/m2 ivgtt” NCT01035385 ↗ |
| Known as | calcium levofolinate | “* Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine [calcium levofolinate]) (IV/2 hours), via a Y connector at the same time as irinotecan” NCT02591030 ↗2“Maintenance treatment (folinic acid/calcium levofolinate + 5-FU) will be administered until progression.” NCT05988814 ↗ “400mg/m², ivdrip, D1; or calcium levofolinate, 200 mg/m², ivdrip, D1” NCT05480280 ↗ |
| Known as | Calciumfolinat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02661971 ↗ |
| Known as | Citrovorum Factor | “5-Fluorouracil, 5-FU, NSC-19893; with Leucovorin calcium, Citrovorum Factor, CF, NSC-3590.” NCT00425152 ↗1“Leucovorin calcium, Citrovorum Factor, CF, NSC-3590” NCT00002471 ↗ |
| Known as | D/L-folinic acid | “folinic acid (either 400 mg/m\^2 D/L-folinic acid or 200 mg/m\^2 L-folinic acid)” NCT01289821 ↗ |
| Known as | dl-leucovorin | “leucovorin \[dl-leucovorin\] 400 mg/m\^2 i.v. infusion over 90 minutes” NCT01085331 ↗1“dl leucovorin\* 400 mg/m² IV infusion over 2 hours” NCT02173990 ↗ |
| Known as | DL-LV | “dextro-levogyre (DL-LV) racemic mixture 400 mg/m²” NCT03982121 ↗ |
| Known as | Elvorin | “folinic acid 200 mg/m² (or Elvorin 400 mg/m²) IV during 2h” NCT04188145 ↗ |
| Known as | Elvorine | “Folfiri.3: Irinotécan 90 mg/m² at day 1 in perfusion over 60 minutes in parralel of folinic acid Folinic acid 400 mg/m² (or 200 mg/m² Elvorine) at day 1 in perfusion over 2 hours” NCT02352337 ↗4“* Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine [calcium levofolinate]) (IV/2 hours), via a Y connector at the same time as irinotecan” NCT02591030 ↗ “Folinic Acid 400 mg/m² (or 200 mg/m² Elvorine) at Day 1 in perfusion over 2 hours” NCT02827201 ↗ “* Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) by 2-hours IV infusion,” NCT03959293 ↗ “Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) IV over 2 hours” NCT03186326 ↗ |
| Known as | EPIC with FUDR and Leucovorin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01815359 ↗ |
| Known as | FOL | “FOLFOX (folinic acid \[FOL, leucovorin\], fluorouracil \[F, 5-FU\], and oxaliplatin \[OX\]) was supplied as solutions for intravenous administration.” NCT00959647 ↗2“mFOLFOX6 is combination of folinic acid (FOL)/leucovorin, 5-fluorouracil and oxaliplatin (OX) which acts as systemic cytotoxic agent.” NCT03250832 ↗ “Leucovorin calcium (folinic acid)(FOL) + 5-fluorouracil (F)+ oxaliplatin (OX)” NCT00551213 ↗ |
| Known as | Folic acid (FA) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04062656 ↗ |
| Known as | folinate calcium | “Hepatic Arterial Infusion Chemotherapy: FOLFOX6 regimen was infused with chemotherapy drugs: oxaliplatin 130 mg/m2 infusion for 2 hours, folinate calcium 400 mg/m2 infusion for...” NCT05290116 ↗ |
| Known as | folinic acid | “Irinotecan will be administered intravenously at a dose of 180 mg/m\^2 along with folinic acid administration intravenously at a dose of 400 mg/m\^2 (racemic) or 200 mg/m\^2...” NCT00778830 ↗311“Patients received either fluorouracil plus folinic acid (folinic acid, 20 mg/m(2), intravenous bolus injection, followed by fluorouracil, 425 mg/m(2) intravenous bolus...” PMID 20823433 ↗ Sep 2010 “Oxaliplatin 85 mg/m2 IV, folinic acid 400 mg/m2 IV (or L-folinic acid 200 mg/m²), and fluorouracil (5-FU) 400 mg/m² IV bolus; followed by 5 FU 2400 mg/m2 as a 46 hour...” NCT06846346 ↗ “mFOLFIRINOX will be dosed as follows: Oxaliplatin 85 mg/m2, followed by folinic acid 400 mg/m2 infused over 120 minutes and irinotecan 135 mg/m2 infused over 90 minutes,...” NCT03099265 ↗ “This phase II trial included patients with clinical T1-T3abN0 low- or mid-rectal adenocarcinoma eligible for endoscopic resection who were treated with 3 months of chemotherapy...” PMID 35981270 ↗ Aug 2022 “The trial TyRosine kinase Inhibitor for the treatment of Chemorefractory Colorectal Cancer (TRICC-C) trial evaluates the addition of nintedanib to mFOLFOX6 (fluorouracil,...” PMID 32930387 ↗ Oct 2020 “This phase II trial tests how well fluorouracil, oxaliplatin and leucovorin calcium (folinic acid) (FOLFOX) with botensilimab and balstilimab given before surgery (neoadjuvant)...” NCT06780787 ↗ “This multicenter phase II non-comparative trial evaluated the addition of aflibercept to infusional 5-fluorouracil/folinic acid (LV5FU2 regimen) as first-line treatment in...” PMID 38672597 ↗ Apr 2024 “The regimen tested consisted of bevacizumab (5 mg/kg), folinic acid(400 mg/m²), 5-fluorouracil (2400 mg/m² for 46 h), oxaliplatin (85 mg/m²) and irinotecan (70 mg/m²...” PMID 39913183 ↗ Feb 2025 “D29 and D43 FOLFIRINOX: Oxaliplatin 85mg / m², Irinotecan 180mg / m², Folinic acid 400 mg / m², 5-fluorouracil 400mg / m² in bolus followed by continuous administration over...” NCT05065801 ↗ “oxaliplatin 85 mg/m2 and folinic acid 400 mg/m2 are administered intravenously for 2 hours on day 1 following by 5-FU at 2,400 mg/m2 by continuous infusion for 46hours every 2...” NCT02226380 ↗ “modified FOLFOX with Oxaliplatin 85 mg/m2 i.v. on day 1; Folinic Acid 400 mg/m2 i.v. on day 1; 5-FU 2,400 mg/m2 i.v. continuous infusion over 48 hours (no bolus!) on days 1 and...” NCT07176312 ↗ “mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) every 2 weeks...” NCT05571644 ↗ “5-fluorouracil 500 mg/m2 and folinic acid 20 mg/m2 infused both bolus weekly for 6 weeks (d1, 8,15, 22, 29 and 36) and oxaliplatin 85 mg / m2 infused over 2 hours at weeks 1,3...” NCT02896803 ↗ “Pilot Study of Hepatic Arterial Infusion (HAI) With Oxaliplatin, Folinic Acid and 5 Fluorouracil (FOLFOX) in Heavily Pre-Treated Patients With Liver-Predominant Metastasis From...” NCT01937507 ↗ “There will be six groups: 1) combination with paclitaxel, 2) combination with topotecan, 3) combination with doxorubicin, 4) combination with 5-fluorouracil, folinic acid, and...” NCT06840886 ↗ “FOLFIRI regimen (irinotecan 180 mg/m2 over 90 minutes concurrently with folinic acid 400 mg/m2 over 2 hours, and then 5-FU 2400 mg/m2 over 46 hours on Days 1 and 15 of each...” NCT05983367 ↗ “Patients continue to receive standard chemotherapy including folinic acid, fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX), gemcitabine plus nab-paclitaxel, or...” NCT03398291 ↗ “folinic acid (also called leucovorin, calcium folinate or FA) fluorouracil (also called 5FU) irinotecan given per institutional standard (intravenously day 1 and day 15 of 28 day cycle)” NCT04587128 ↗ “mFOLFOX6 consisting of Folinic acid (Leucovorin) 400 mg/m2 (D,L racemic form) or 200 mg/m2 (L-isomer form [levo leucovorin]), 5-fluorouracil (5-FU) 2400 mg/m2 and Oxaliplatin 85 mg/m2” NCT05052099 ↗ “Modified FOLFIRINOX regimen comprised oxaliplatin 85mg/m2 + irinotecan 180mg/m2 + Folinic acid 400 mg/m2 at day1, then 5-FU given as a continuous infusion over 46h every two weeks.” NCT03875781 ↗ “Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.” PMID 24982456 ↗ Jun 2014 “mFOLFIRINOX (oxaliplatin 85 mg/m2, irinotecan 180 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycles” NCT05954078 ↗ “mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycles” NCT04338191 ↗ “mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150-165 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400-2800mg/m2 as a 46-48 hour continuous infusion on day 1)” NCT05200299 ↗ “folinic acid (also known as: 5-formyl tetrahydrofolic acid and leucovorin) intravenous infusion, and 5-FU (also known as; fluorouracil) intravenous bolus/intravenous infusion” NCT05004350 ↗ “Docetaxel 50 mg/m² IV over 1 hour plus Oxaliplatin 85 mg/m² IV over 2 hours plus Folinic Acid 200 mg/m² IV over 1 hour plus 5-FU 2600 mg/m² IV over 24 hours every 2 weeks” NCT05504720 ↗ “In the high dose MTX protocol, the patients will receive 100 mg/m2 intravenous (IV) MTX bolus followed by 200 mg/m2IV MTX infused over 12 hours followed by folinic acid” NCT03280979 ↗ “Oxaliplatin 85 mg/m2,irinotecan 180 mg/m2, folinic acid 400 mg/m2, 5'Fluouracilo 400 mg / m2, 5 'fluorouracil 2400 mg/m2 continuous intravenous infusion of 46 hours.” NCT01454180 ↗ “The FOLFIRINOX scheme, composed of 5-fluorouracil / folinic acid, oxaliplatin and irinotecan, is recommended as neoadjuvant treatment, but the response is still low.” NCT04010552 ↗ “FOLFIRI iv every 14 days (Irinotecan 180 mg/sqm, Folinic Acid 400 mg/sqm, 5Fluorouracil 400 mg/sqm iv bolus and 2400 mg/sqm iv continuous infusion over 46-48 hours).” NCT06640166 ↗ “Patients will receive folinic acid (400 mg/m²)/5-fluorouracil (400 mg/m² as bolus followed by 2400 mg/m2 as a 46-hour infusion)/oxaliplatin (85 mg/m2) every 14 days” PMID 29942666 ↗ Jun 2018 “cetuximab 500mg/m2 + oxaliplatin 85 mg/m2 + irinotecan 165 mg/m2 + folinic acid 400 mg/m2 + 5-fluorouracil 2400 mg/m2 46h infusion starting on day 1, every 2 weeks” NCT04687631 ↗ “Each course of chemotherapy consisted of fluorouracil (350 mg/m(2) per day intravenous bolus) and folinic acid (leucovorin; 20 mg/m(2) per day intravenous bolus).” PMID 24440473 ↗ Jan 2014 “mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1)” NCT05427669 ↗ “The subjects will be administered folinic acid (Leucovorin; LV), Fluorouracil (5-FU) and Oxaliplatin (FOLFOX) + Bevacizumab/Cetuximab by intravenous infusion.” NCT02826837 ↗ “Pyrimethamine + sulfadiazine group : Pyrimethamine 50 mg once daily orally and sulfadiazine 1g tid. orally, with supplemental folinic acid 50 mg once a week.” NCT01189448 ↗ “A Phase II Study of Oxaliplatin in Association With 5FU and Folinic Acid in the Treatment of Subjects With Non-Surgical or Advanced Metastatic Gastric Cancer” NCT00611507 ↗ “Patients allocated to receive conventional chemotherapy will be treated with methotrexate (1 mg/kg intramuscular) with rescue of folinic acid (15mg orally).” NCT04756713 ↗ “mFOLFOX6 (day 1, oxaliplatin 85 mg/m², folinic acid 400 mg/m², and fluorouracil 400 mg/m² intravenous bolus, then 2400 mg/m² over 46 h continuous infusion)” NCT01564810 ↗ “Adjuvant chemotherapy consists of 6 cycles of 5FU/folinic acid and oxaliplatin (FOLFOX) every 2 weeks, or 4 cycles of capecitabine and oxaliplatin (CAPOX).” NCT07188025 ↗ “oxaliplatin 85 mg/m2, irinotecan 165 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1” NCT04781270 ↗ “FOLFOX (folinic acid \[FOL, leucovorin\], fluorouracil \[F, 5-FU\], and oxaliplatin \[OX\]) was supplied as solutions for intravenous administration.” NCT00959647 ↗ “HAIC was adopted of the FOFOLX 6 program, Folinic acid+5-fluorouracil+Oxaliplatin, 21 days between second HAIC treatments with a window of ±3 days.” NCT06463444 ↗ “Combination of chemotherapy administered every 2 weeks: oxaliplatin (85mg/m2), 5-Fluorouracil (2400mg/m2) and folinic acid (=leucovorin, 400mg/m2)” NCT03176264 ↗ “Standard chemotherapy FOLFIRI (5-fluorouracil, folinic acid, and irinotecan) will be administered intravenously every 14 days of a 28-day cycle.” NCT06747845 ↗ “bidirectional hyperthermic intraperitoneal chemotherapy (HIPEC) with 400 mg/sqm 5-FU + 20 mg/sqm folinic acid IV and 300 mg/sqm oxaliplatin IP” NCT01540344 ↗ “Folinic acid will be administered as a 200 mg/m2 intravenous infusion over 120 minutes before 5- fluorouracil infusion (day 1) every 2 weeks.” NCT04425239 ↗ “2 hour IV infusion of oxaliplatin, folinic acid, and fluorouracil followed by a continuous 46-hour infusion of fluorouracil every two weeks” NCT05480306 ↗ “* Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine [calcium levofolinate]) (IV/2 hours), via a Y connector at the same time as irinotecan” NCT02591030 ↗ “Folinic acid 400 mg/m² (racemic form) or 200 mg/m² (L-form) in 250 ml glucose 5% solution given as a 2 hours IV infusion on days 1 and 15” NCT04167007 ↗ “Participants with UGT1A1\*/\*1 genotype will receive escalating doses of FOLFIRI (folinic acid+fluorouracil+irinotecan) and bevacizumab.” NCT01183494 ↗ “FOLFOX is a chemotherapy regimen for treatment of colorectal cancer, made up of the drugs folinic acid, fluorouracil, and oxaliplatin.” NCT06225843 ↗ “adjuvant chemotherapy with folinic acid (or leucovorin), fluorouracil, and oxaliplatin (FOLFOX) versus the current standard treatment” PMID 32264919 ↗ Apr 2020 “mFOLFOX6 is combination of folinic acid (FOL)/leucovorin, 5-fluorouracil and oxaliplatin (OX) which acts as systemic cytotoxic agent.” NCT03250832 ↗ “FOLFOX 6 treatment consists of intravenous (IV) oxaliplatin (100 milligram per meter\^2\[mg/m\^2\]), and folinic acid (400 mg/m\^2)” NCT00387387 ↗ “Post operative adjuvant chemotherapy: 5FU (425mg/m2) preceded by Folinic acid (20mg/m2) delivered over 5 days for 6 monthly cycles” NCT00145769 ↗ “5-fluorouracil, Folinic acid and Irinotecan will be administered by intravenous infusion on Day 1 and 15 in 28-day dosing cycles.” NCT01472016 ↗ “Folinic acid at 400 mg/m2 given as a 90-min infusion immediately after oxaliplatin, and concurrently with irinotecan (Camptosar).” NCT03374852 ↗ “FOLFIRINOX (14-day cycle) included oxaliplatin (standard dose), folinic acid, fluorouracil and irinotecan (150 or 180mg/m²).” PMID 38987363 ↗ Jul 2024 “concurrently with folinic acid 400 mg/m\^2 (d,I-racemic form, or 200 mg/m\^2 I-isomer form) IV administered over 120 minutes” NCT00636610 ↗ “FOL - folinic acid (leucovorin), a vitamin B derivative that modulates/potentiates/reduces the side effects of fluorouracil” NCT01523457 ↗ “Folinic Acid 400 mg/m2, iv, d1, q2w, 5-FU 400 mg/m2 IV bolus d1 then 5-FU 2400 mg/m2 IV infusion over 46 to 48 hours, q2w.” NCT06841679 ↗ “The LV5FU2 regimen includes folinic acid (400 mg/m², or 200 mg/m² if levo-leucovorin is used) as a two-hour IV infusion” NCT07124884 ↗ “OXALIPLATIN 85 mg/m2; FOLINIC ACID 400 mg/m2; 5-FU 400 mg/m2 IV bolus; 5-FU 2400 mg/m2 continuous infusion for 46 hours” NCT01161316 ↗ “During the continuous intraperitoneal infusion of fluorouracil, 50 mg of folinic acid is administered intravenously.” NCT05913674 ↗ “Participants will receive IV infusion of FOLFOX (5-FU, oxaliplatin, and folinic acid) as stated in arm description.” NCT04068610 ↗ “Folinic acid: 400 mg/m² intravenous over 30 minutes or L-folinic acid (racemic form L) 200 mg/m² over 30 minutes” NCT03719924 ↗ “Modified FOLFIRINOX (Folinic acid/Leucovorin, 5-Fluouracil, Irinotecan, Oxaliplatin) administered intravenously.” NCT04469556 ↗ “the control group (n=28) which received 6 cycles of folinic acid, fluorouracil and irinotecan (FOLFIRI) regimen” PMID 35022282 ↗ Jan 2022 “followed by folinic acid 400 mg/m² (racemic mixture) (or 200 mg/m² if L-folinic acid) IV infusion over 2 hours” NCT02967289 ↗ “Folinic acid 400 mg/m² (racemic mixture) (or 200 mg/m² if L-folinic acid is used), IV infusion over 2 hours.” NCT01526135 ↗ “Oxaliplatin, folinic acid, irinotecan and 5-Fluoruracil will be administered on day 1 and 15 every 28 days” NCT04793932 ↗ “Folfox chemotherapy (folinic acid, fluorouracil and oxaliplatin) for 6 weeks (3 courses) before surgery.” NCT06293625 ↗ “Maintenance treatment (folinic acid/calcium levofolinate + 5-FU) will be administered until progression.” NCT05988814 ↗ “either cetuximab and irinotecan or cetuximab and FOLFIRI (folinic acid, fluorouracil, and irinotecan)” PMID 31566309 ↗ Sep 2019 “FOLFOX (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion” NCT05832398 ↗ “FOLFIRI (leucovorin [folinic acid], fluorouracil, and irinotecan) plus cetuximab induction therapy” PMID 37721754 ↗ Sep 2023 “receiving Sunitinib in Addition to 5-FU, Folinic Acid and Irinotecan (FOLFIRI) as 1st Line Therapy” NCT00806663 ↗ “concurrently with folinic acid 400 mg/m² (or 200 mg/m² if L-folinic acid) as a 2 h IV infusion” NCT06475352 ↗ “Folinic acid at 400 mg/m2 given as a 90 min (1.5hr) infusion immediately after Oxaliplatin” NCT03504423 ↗ “FOL : folinic acid (leucovorin), a vitamin B derivative that enhances the effects of 5-FU” NCT05262452 ↗ “5-fluorouracil, Folinic acid and Irinotecan will be administered by intravenous infusion.” NCT01946074 ↗ “Oxaliplatin 85 mg/m² simultaneously with folinic acid 400 mg/m² as a 2-hour IV infusion” NCT00382720 ↗ “standard care FOLFOX-based (5-fluorouracil, folinic acid and oxaliplatin) chemotherapy” PMID 25872567 ↗ Mar 2015 “folinic acid: 400 mg/m² simultaneously in 2 hours at D1 during the irinotecan infusion” NCT01804790 ↗ “Folinic acid (400 mg/m2) IV infusion through a drip into the bloodstream over 2 hours.” NCT04926545 ↗ “Leucovorin: 400mg/m2 folinic acid (racemid dl) in a continuous infusion for 2 hours.” NCT06783491 ↗ “Folinic acid (Leucovorin): 400 mg/m² IV infusion over 2 hours, Day 1, Every 2 weeks” NCT07204574 ↗ “folinic acid 400 mg/m2 or calcium levofolinate 200 mg/m2 given as a 2-h IV infusion” NCT06757244 ↗ “FOL - folinic acid (leucovorin), a vitamin B derivative with multiple applications” NCT06047379 ↗ “Calcium folinate (folinic acid) 20 mg/m2/day intravenously on days 1-4 and 33-35.” NCT06758830 ↗ “Folinic Acid 400 mg/m² (or 200 mg/m² Elvorine) at Day 1 in perfusion over 2 hours” NCT02827201 ↗ “concurrently with folinic acid (leucovorin) 400 mg/m2 intravenously over 2 hours” NCT03597581 ↗ “The specific agents are Oxaliplatin, Folinic Acid, Irinotecan, and Fluorouracil.” NCT03941093 ↗ “oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid)” NCT02658214 ↗ “HAIC was adopted the FOFOLX6 program (Folinic acid+5-fluorouracil+Oxaliplatin).” NCT06311942 ↗ “mFOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin, and irinotecan) in LARC” PMID 37370032 ↗ Jun 2023 “Hour 0: Folinic Acid 400 mg/m² (DL form) or 200 mg/m2 (L form) IV 2-h infusion” NCT01646554 ↗ “Leucovorin calcium (folinic acid)(FOL) + 5-fluorouracil (F)+ oxaliplatin (OX)” NCT00551213 ↗ “BOLD-100 +/- Folinic acid (leucovorin), Fluorouracil (5-FU), and Oxaliplatin.” NCT04421820 ↗ “* Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) by 2-hours IV infusion,” NCT03959293 ↗ “Eloxatin (oxaliplatin), leucovorin (folinic acid) and 5-Fluorouracil (5-FU)” NCT00265850 ↗ “irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil” NCT04230187 ↗ “Oxaliplatin (Eloxatin), 5FU (5-Fluorouracil) and Leucovorin (Folinic Acid)” NCT00580073 ↗ “high-dose, infusional fluorouracil (FU) and leucovorin (folinic acid [FA])” PMID 15939923 ↗ Jun 2005 “folinic acid (leucovorin), fluorouracil (5-FU), and oxaliplatin (mFOLFOX6)” NCT02102022 ↗ “FOLFOX (folinic acid [leucovorin calcium], fluorouracil, and oxaliplatin)” PMID 28006055 ↗ Apr 2017 “Leucovorin (folinic acid) is a vitamin which enhances the effect of 5-FU.” NCT00199797 ↗ “concurrently with Folinic Acid (400 mg/m\^2 IV, infused over 120 minutes)” NCT02568046 ↗ “(Levo) Folinic Acid (200) 400mg/m², iv, d1; total 5-FU 2400mg/m², iv gtt” NCT07070713 ↗ “Folinic acid 400 mg/m2 (or Leucovorin 200 mg/m²) as a 2-hour IV infusion” NCT07616362 ↗ “a regimen combining 5-fluorouracil (5-FU), folinic acid, and irinotecan” PMID 19826418 ↗ Oct 2009 “Folinic Acid (Leucovorin)\* 400 mg/m2 IV in 250 ml D5W over 120 minutes” NCT01274962 ↗ “Folinic acid 400 mg / m2 Day1 in 2 h (during the irinotecan infusion)” NCT02352337 ↗ “Combination of 5-Fluorouracil/Folinic Acid, Irinotecan, Oxaliplatin” NCT02355119 ↗ “Folinic acid 400 mg/m² as 2-hour IV infusion, in Y with oxaliplatin” NCT06278545 ↗ “folinic acid (FA) 400 mg/m2 on days 1 and 15 and q d29 for 6 cycles” NCT01703390 ↗ “400 mg/m2 folinic acid or 200 mg/m² levofolinate in a 2-h infusion” NCT07061080 ↗ “Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) IV over 2 hours” NCT03186326 ↗ “folinic acid [FA] + fluorouracil [5-FU] + oxaliplatin [mFOLFOX-6]” NCT01111604 ↗ “Folinic acid 400 mg/m2, given as a 2-hour intravenous infusion D1” NCT02125136 ↗ “leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin” NCT04418895 ↗ “Folinic acid 400 mg intravenously on Days 1 and 15 every 4 weeks” NCT03600623 ↗ “leucovorin calcium (folinic acid), fluorouracil, and irinotecan” NCT07011576 ↗ “folinic acid (day 1; 400 mg/m(2) racemic or 200 mg/m(2) L-form)” PMID 25627002 ↗ Jan 2015 “Oral Folinic Acid (90 mg in 3 daily divided doses) on days 1-21” NCT00439517 ↗ “Folinic acid 200mg/m2 as a 120 minute infusion on days 1 and 2” NCT00885885 ↗ “* mFFX: Oxaliplatin, Folinic acid, Fluorouracil and Irinotecan” NCT06518538 ↗ “Leucovorin/folinic acid- 400 mg/m2, IV over 90 minutes, day 1” NCT05926206 ↗ “Folinic acid 200 mg/m2 over 24 hours day 1, 8, 15, 22, 29, 36” NCT01123811 ↗ “leucovorin/folinic acid is a vitamin to make 5-FU work well” NCT04361708 ↗ “folinic acid 400mg/m2 (or L-folinic acid 200 mg/m2) over 2h” NCT07118800 ↗ “folinic acid 200 mg/m² (or Elvorin 400 mg/m²) IV during 2h” NCT04188145 ↗ “* folinic acid: 400 mg/m2 (DL form) or 200 mg/m2 (L form)” NCT02514278 ↗ “folinic acid (dl racemic): 400 mg/m2 intravenous infusion” NCT02970916 ↗ “FOFOLX6 program, Folinic acid+5-fluorouracil+Oxaliplatin” NCT06311916 ↗ “* Folinic acid: 350 mg flat dose, IV over 2 hours, day 1” NCT04151277 ↗ “* Folinic acid: 350mg flat dose, IV over 2 hours, day 1.” NCT04176952 ↗ “folinic acid 400 mg/m² IV (or L-folinic acid 200 mg/m²)” NCT07437287 ↗ “Folinic Acid 400 mg/m² (or 200 mg/m² if L-folinic acid)” NCT05476796 ↗ “folinic acid 400 mg/m2 IV (or L-folinic acid 200 mg/m²)” NCT07359456 ↗ “Folinic acid (D1) H+1: 400mg/m² IV infusion over 120min” NCT04392479 ↗ “folinic acid, infusional fluorouracil, and oxaliplatin” NCT00958737 ↗ “5-Fluorouracil and Folinic Acid (Leucovorin) Regimens” NCT03703063 ↗ “FOLFIRI (Irinotecan, 5-fluorouracil and Folinic Acid)” NCT02605044 ↗ “Folinic acid: 400 mg/m2 IV infusion for over 2 hours” NCT04810585 ↗ “Folinic acid 200mg/m2 iv infusion day 1 over 2 hours” NCT03399071 ↗ “Minimum of 1 mg/day oral (or folinic acid 5 mg/week)” NCT00243412 ↗ “Leucovorin (folinic acid) 400 mg/m\\(\^2\\), IV, d1” NCT06650332 ↗ “leucovorin 200 mg/m² IV (or folinic acid 400 mg/m²)” NCT06529718 ↗ “oxaliplatin folinic acid irinotecan 5FU oxaliplatin” NCT02676349 ↗ “Folinic acid, Irinotecan, fluorouracil, oxaliplatin” NCT03822936 ↗ “folinic acid 350 mg/m² by 2-h intravenous infusion” NCT03530267 ↗ “Folinic acid (racemic) 400 mg/m² IV, 120 min day 1” NCT03688230 ↗ “Folinic acid (400 mg/m2) IV over 2 hours on Day 1.” NCT06055179 ↗ “5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI)” NCT00780169 ↗ “Folinic acid: 400 mg/m², 1-2 h IV infusion on d1” NCT05008809 ↗ “FOLFOX (folinic acid, fluorouracil, oxaliplatin)” NCT00994864 ↗ “Folinic acid (FA): 400 mg/m² IV/2h (day 1, q2w),” NCT03828227 ↗ “Folinic acid 200 mg/m² 2-hr IV infusion on day 1” NCT02359968 ↗ “Folinic acid (leucovorin) 400 mg/m2 IV infusion” NCT04145193 ↗ “Folinic acid: 400mg/m², 1-2h IV Infusion on d1” NCT07004413 ↗ “5 mg of folinic acid taken orally once a week” NCT05363917 ↗ “* Folinic acid 400 mg/m2 as 0.5 hour infusion” NCT03468335 ↗ “irinotecan 150 mg/m², folinic acid 400 mg/m²” NCT06890624 ↗ “Folinic Acid, 5-FU, Oxaliplatin, Irinotecan” NCT05466799 ↗ “* Fluorouracil * Oxaliplatin * Folinic acid” NCT04793958 ↗ “Folinic acid, 5-FU, Irinotecan, Oxaliplatin” NCT06079346 ↗ “FUFA 5-flurouracil and folinic acid control” NCT01212718 ↗ “Folinic acid 400 mg/ m2 day 1 i.v. 120 min” NCT01704703 ↗ “Na folinic acid 200 mg/m2 on D1, 8, 15, 22” NCT03331640 ↗ “Folinic acid: 400 mg/m2, 2h i.v., on day 1” NCT04495088 ↗ “Folinic acid (D,L) 400 mg/m² (2.0 h i.v.)” NCT00153998 ↗ “mFOLFOX (5-FU+Oxalipatin+folinic acid)” NCT05065957 ↗ “Folinic acid; 200 mg/m2 ; day 1 and 2” NCT00202787 ↗ “folinic acid 400 mg/ m\^2 2h infusion” NCT01827553 ↗ “Folinic acid + 5-FU (5-Fluorouracil)” NCT01991873 ↗ “Folinic Acid will be administered at” NCT05585320 ↗ “leucovorin (folinic acid) 300 mg/m2” NCT00384878 ↗ “Folinic acid 400 mg/m2 IV on day 1” NCT04348045 ↗ “Folinic acid 400 mg/m2 \~1 h day 1” NCT06899477 ↗ “leucovorin calcium (folinic acid)” NCT00003063 ↗ “Folinic acid: 400 mg/sqm, 2h-iv;” NCT03561142 ↗ “Leucovorin calcium/folinic acid” NCT05346484 ↗ “followed by folinic acid rescue” NCT02701517 ↗ “Folinic acid: 400 mg/sqm, 2h-iv” NCT02363374 ↗ “5-FU, folinic acid, oxaliplatin” NCT01508000 ↗ “folinic acid 200 mg/m2 (30 min)” NCT00785421 ↗ “Leucovorin (Folinic Acid)” NCT01260415 ↗ “* folinic acid: 400 mg/m2” NCT03879109 ↗ “folinic acid 400 mg/m\^2” NCT03806309 ↗ “Drug: Folinic Acid” NCT02022358 ↗ “folinic acid” NCT05628038 ↗ |
| Known as | folinic acid (FA) | “folinic acid (FA)” NCT04617457 ↗ |
| Known as | Folinic acid (FA, i.e. Leucovorin, Wyeth) | “Folinic acid (FA, i.e. Leucovorin®, Wyeth)” NCT00153998 ↗ |
| Known as | Folinic acid (leucovorin) | “Folinic acid (leucovorin)” NCT01571024 ↗1“Folinic Acid (Leucovorin)” NCT02568046 ↗ |
| Known as | Folinic acid calcium salt | “Folinic acid calcium salt (calcium folinate) is the bioactive metabolite of folic acid that does not require reduction by dihydrofolate reductase (DHFR).” NCT04723134 ↗ |
| Known as | FOLINORAL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02551380 ↗ |
| Known as | L-folinic acid | “Oxaliplatin 85 mg/m2 IV, folinic acid 400 mg/m2 IV (or L-folinic acid 200 mg/m²), and fluorouracil (5-FU) 400 mg/m² IV bolus; followed by 5 FU 2400 mg/m2 as a 46 hour...” NCT06846346 ↗4“folinic acid (either 400 mg/m\^2 D/L-folinic acid or 200 mg/m\^2 L-folinic acid)” NCT01289821 ↗ “folinic acid 400mg/m2 (or L-folinic acid 200 mg/m2) over 2h” NCT07118800 ↗ “folinic acid 400 mg/m2 IV (or L-folinic acid 200 mg/m²)” NCT07359456 ↗ “folinic acid 400 mg/m² IV (or L-folinic acid 200 mg/m²)” NCT07437287 ↗ |
| Known as | l-leucovorin | “Phase I / II Study of Irinotecan (CPT-11) Combined With l-Leucovorin (l-LV) and 5-FU in Patients With Advanced Colorectal Cancer” NCT00209625 ↗1“L-Leucovorin 200 mg/sqm iv over 2 hours, day 1” NCT02904031 ↗ |
| Known as | l-LV | “Phase I / II Study of Irinotecan (CPT-11) Combined With l-Leucovorin (l-LV) and 5-FU in Patients With Advanced Colorectal Cancer” NCT00209625 ↗6“Leucovorin (l-LV) 200mg/m2 IV over 2 hours on Day 1, 15” NCT02102789 ↗ “Leucovorin (l-LV) 200mg/m2 ivd over 2 hours on Day 1” NCT03493048 ↗ “Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1” NCT04224402 ↗ “Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1” NCT04084496 ↗ “Leucovorin (LV) levogyre form (LLV) 200 mg/m²” NCT03982121 ↗ “Leucovorin(l-LV) 400 mg/m2 IV over 2 hours” NCT06153368 ↗ |
| Known as | l-LV (dl-LV) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01996306 ↗ |
| Known as | LCV | “To study the safety and effectiveness of trimetrexate (TMTX) plus leucovorin calcium rescue (LCV) in the treatment of Pneumocystis carinii pneumonia (PCP) in patients who have...” NCT00000724 ↗7“To evaluate the safety and effectiveness of trimetrexate (TMTX) given at increasing doses along with the leucovorin calcium (LCV) for treating Pneumocystis carinii pneumonia...” NCT00000998 ↗ “This study compares therapy with trimetrexate (TMTX) and leucovorin (LCV) to standard therapy and standard therapy plus high-dose steroids (methylprednisolone).” NCT00000730 ↗ “TMTX, in combination with leucovorin (LCV), did not cause severe toxicity in a preliminary trial.” NCT00001013 ↗ “Leucovorin (LCV) IV or PO begins 6 hours after MTX has been completed over 6 hours for 8 doses” NCT00000723 ↗ “investigational drug therapy (trimetrexate plus leucovorin calcium (TMTX / LCV))” NCT00000714 ↗ “investigational drug trimetrexate (TMTX) with leucovorin rescue (LCV)” NCT00001016 ↗ “LCV, 400 mg/m2 administered over 2 hours concurrent with oxaliplatin” NCT05378867 ↗ |
| Known as | leucovorin (Folina tab, TTY Biopharm, TW) | “leucovorin (Folina tab, TTY Biopharm, TW)” NCT04999332 ↗ |
| Known as | leucovorin (FOLinic acid) | “leucovorin (FOLinic acid)” NCT01420874 ↗1“Leucovorin (Folinic Acid)” NCT01749956 ↗ |
| Known as | Leucovorin (LV) | “Leucovorin (LV)” NCT02402972 ↗ |
| Known as | leucovorin calcium | “All patients receive leucovorin calcium (CF) IV once at hour 36 after initiation of MTX infusion, once every 3 hours between hours 36-48, and continuing once every 6 hours...” NCT00040690 ↗322“OBJECTIVES: I. Determine the safety, tolerability, maximum tolerated dose, and dose limiting toxicity of oral SCH 66336 with fluorouracil and leucovorin calcium in patients...” NCT00003956 ↗ “Patients received modified FOLFIRINOX treatment (85 mg/m2 of oxaliplatin, 180 mg/m2 of irinotecan hydrochloride, 400 mg/m2 of leucovorin calcium, and then 2400 mg/m2 of...” PMID 27275632 ↗ Aug 2016 “TPF (Paclitaxel micelles or albumin-bound paclitaxel 100 mg/m2, cisplatin 30 mg/m2, fluorouracil 200 mg/m2 IV drip + 1000 mg/m2 pump for 44 hours, leucovorin/calcium 200 mg) +...” NCT07469241 ↗ “Patients receive irinotecan hydrochloride IV over 90 minutes and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously over 46 hours on days 1 and 2 (FOLFIRI).” NCT00537121 ↗ “Patients receive FOLFOX7 chemotherapy comprising oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV over 46 hours beginning on day 1.” NCT00072553 ↗ “Patients receive bevacizumab IV over 30-90 minutes, irinotecan hydrochloride IV over 90 minutes, leucovorin calcium IV over 2 hours, and fluorouracil IV over 46 hours on day 1.” NCT00628810 ↗ “Beginning 42 days after surgery, T2 patients receive leucovorin calcium (CF) IV over 2 hours with fluorouracil (5-FU) IV bolus 1 hour into the infusion once weekly for 6 weeks.” NCT00023751 ↗ “Drugs used in chemotherapy, such as leucovorin calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin, work in different ways to stop the growth of tumor cells” NCT02047474 ↗ “During the first period of this study, an initial pharmacological assessment of fluorouracil administered intravenously along with oral leucovorin calcium is made.” NCT00001579 ↗ “Leucovorin Calcium for Injection is supplied in vials ranging from 50-500 mg and available as an injectable solution or lyophilized powder for reconstitution.” NCT04083235 ↗ “mFOLFOX6: oxaliplatin 85 mg/m2 IV d1 + leucovorin calcium 400 mg/m2 IV d1 + 5-FU 400 mg/m2 IV bolus d1 + 5-FU 2400 mg/m2 continuous IV over 46-48 hours d1-2.” NCT02965248 ↗ “mFOLFOX6:oxaliplatin 85 mg/m2 IV d1 + leucovorin calcium 400 mg/m2 IV d1 + 5-FU 400 mg/m2 IV bolus d1 + 5-FU 2400 mg/m2 continuous IV over 46-48 hours d1-2.” NCT04370925 ↗ “Patients receive oxaliplatin and leucovorin (L-leucovorin or leucovorin calcium) IV over 2 hours on day 1 and fluorouracil IV over 46 hours on days 1-2.” NCT01263171 ↗ “all patients receive 6 months of chemotherapy consisting of leucovorin calcium IV followed by fluorouracil IV over 10 minutes on days 1-5 every 4 weeks” NCT00005944 ↗ “leucovorin calcium IV on days 2, 16, and 30; and leucovorin PO calcium every 6 hours for a total of 8 doses each on days 3-4, 17-18, and 31-32.” NCT01256398 ↗ “Leucovorin calcium: A dose of 200 mg/m² infused intravenously over 30 minutes, or according to the clinical practice of the research center.” NCT07542002 ↗ “For each cycle, leucovorin calcium 200 mg/m2 would be intravenously administered for 2 hours from beginning of 5-fluorouracil infusion.” NCT05171166 ↗ “Arm I: Patients receive leucovorin calcium IV over 2 hours followed by fluorouracil IV over 24 hours on days 1, 8, 15, 22, 29, and 36.” NCT00004885 ↗ “Patients receive oral leucovorin calcium every 12 hours for 2 doses beginning 24 hours after the last dose of aminopterin each week.” NCT00003305 ↗ “mFOLFOX6 is a combination chemotherapy regimen including the drugs leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin.” NCT04396821 ↗ “sequential fluorouracil (5-FU) and leucovorin calcium, panitumumab, modified 5-FU, leucovorin calcium, and oxaliplatin (mFOLFOX6)” NCT00610948 ↗ “Patients receive floxuridine, dexamethasone, and leucovorin calcium (CF) via continuous hepatic artery infusion on days 1-14.” NCT00002716 ↗ “Patients receive oxaliplatin IV over 2 hours once every 2 weeks and fluorouracil IV and leucovorin calcium IV once weekly.” NCT00004206 ↗ “Patients receive leucovorin calcium IV over 2 hours and fluorouracil IV continuously over 22 hours on days 1 and 2.” NCT00303771 ↗ “HAIC: oxaliplatin 100 mg/m2, leucovorin calcium 200 mg/m2, fluorouracil 2000 mg/m2 24-hour drip, q4w, 2 cycles;” NCT05511051 ↗ “leucovorin calcium (CF) (or levofolinic acid) orally or IV beginning 36 hours after initiation of MTX infusion” NCT00003728 ↗ “Patients receive irinotecan hydrochloride IV over 90 minutes and leucovorin calcium IV over 2 hours on day 1” NCT00416767 ↗ “Patients receive oral fluorouracil-uracil and oral leucovorin calcium (Orzel) every 8 hours for 28 days.” NCT00004860 ↗ “Patients receive leucovorin calcium IV over 2 hours and fluorouracil IV continuously on days 1 and 2.” NCT00016952 ↗ “Patients receive fluorouracil (5-FU) IV continuously and leucovorin calcium (CF) IV on days 1 and 2.” NCT00046995 ↗ “FOLFIRI chemotherapy comprising irinotecan hydrochloride, fluorouracil, and leucovorin calcium” NCT00524186 ↗ “folinic acid \[leucovorin calcium\], fluorouracil, and irinotecan \[irinotecan hydrochloride\]” NCT01941173 ↗ “5-Fluorouracil, 5-FU, NSC-19893; with Leucovorin calcium, Citrovorum Factor, CF, NSC-3590.” NCT00425152 ↗ “leucovorin calcium (LV) with or without adbellizumab for resectable pancreatic cancer” NCT06172036 ↗ “leucovorin calcium 400 mg/m\^2 administered as an intravenous bolus over 2 hours” NCT01478594 ↗ “oral fluorouracil-uracil plus oral leucovorin calcium twice a day on days 1-21” NCT00009815 ↗ “Leucovorin calcium (folinic acid)(FOL) + 5-fluorouracil (F)+ oxaliplatin (OX)” NCT00551213 ↗ “Combination of oxaliplatin, fluorouracil, irinotecan, leucovorin calcium” NCT06572813 ↗ “Patients receive leucovorin calcium IV and fluorouracil IV on days 1-5.” NCT00058201 ↗ “Leucovorin calcium 400mg/m\^2 intravenous infusion for 2 hours, day 1” NCT06368063 ↗ “leucovorin calcium 200 mg/m² intra-arterial infusion over 2 hours” NCT07522411 ↗ “leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin” NCT04418895 ↗ “Leucovorin calcium 400 mg/m², intravenous infusion on Day 1” NCT07381400 ↗ “leucovorin calcium orally or IV every 6 hours for 3 days” NCT00002489 ↗ “CF Leucovorin calcium, NSC-3590 CTX Cyclophosphamide” NCT00002704 ↗ “Oxaliplatin 50 mg + 5-FU 1.5 g + leucovorin calcium.” NCT05124002 ↗ “Leucovorin calcium, Citrovorum Factor, CF, NSC-3590” NCT00002471 ↗ “Leucovorin calcium (350 mg/m2 IV over 2 h on day 1)” NCT05948072 ↗ “leucovorin calcium IV over 2 hours on days 1 and 2” NCT00005036 ↗ “leucovorin calcium IV over 2 hours on days 1 and 2” NCT00039611 ↗ “TEGAFOX (oxaliplatin+ Tegafur +Leucovorin Calcium)” NCT02817425 ↗ “leucovorin calcium (LV) and oxaliplatin (FOLFOX)” NCT02291289 ↗ “leucovorin calcium IV on days 2, 16, and 30” NCT00061945 ↗ “leucovorin calcium (CF) IV over 15 minutes” NCT00020501 ↗ “FOLFIRI=Irinotecan+Leucovorin Calcium+5-FU” NCT06621563 ↗ “leucovorin calcium PO or IV on days 3-6” NCT01412879 ↗ “leucovorin calcium (CF) IV over 2 hours” NCT00066846 ↗ “with Leucovorin calcium, CF, NSC-3590.” NCT00002692 ↗ “leucovorin calcium IV over 2 hours” NCT00008294 ↗ “leucovorin calcium (folinic acid)” NCT00003063 ↗ “Drug: leucovorin calcium Given IV” NCT03641976 ↗ “leucovorin calcium orally or IV” NCT00550992 ↗ “Leucovorin calcium/folinic acid” NCT05346484 ↗ “Leucovorin calcium 400 mg/m\^2” NCT06519578 ↗ “Leucovorin Calcium Injection” NCT03127124 ↗ “LV \[Leucovorin calcium\]” NCT04009876 ↗ “Drug: leucovorin calcium” NCT00003700 ↗ “Drug: leucovorin calcium” NCT00080951 ↗ “Drug: Leucovorin Calcium” NCT04927780 ↗ “Drug: leucovorin calcium” NCT00544414 ↗ “Drug: leucovorin calcium” NCT00002756 ↗ “Drug: leucovorin calcium” NCT02015819 ↗ “Drug: leucovorin calcium” NCT00005977 ↗ “Drug: Leucovorin Calcium” NCT00653068 ↗ “Drug: leucovorin calcium” NCT00009893 ↗ “Drug: leucovorin calcium” NCT00118261 ↗ “Drug: Leucovorin Calcium” NCT06821997 ↗ “Drug: Leucovorin Calcium” NCT02573220 ↗ “Drug: Leucovorin Calcium” NCT00002463 ↗ “Drug: Leucovorin Calcium” NCT04535401 ↗ “Drug: Leucovorin Calcium” NCT03300609 ↗ “Drug: leucovorin calcium” NCT00002571 ↗ “Drug: leucovorin calcium” NCT00602329 ↗ “Drug: leucovorin calcium” NCT00049569 ↗ “Drug: Leucovorin calcium” NCT02246049 ↗ “Drug: leucovorin calcium” NCT00039130 ↗ “Drug: leucovorin calcium” NCT00112658 ↗ “Drug: leucovorin calcium” NCT00004228 ↗ “Drug: Leucovorin Calcium” NCT04205968 ↗ “Drug: leucovorin calcium” NCT00952029 ↗ “Drug: Leucovorin Calcium” NCT04233866 ↗ “leucovorin calcium” NCT00004005 ↗ “Leucovorin Calcium” NCT00591123 ↗ “leucovorin calcium” NCT00010088 ↗ “leucovorin calcium” NCT00005607 ↗ “leucovorin calcium” NCT00026273 ↗ “leucovorin calcium” NCT00075738 ↗ |
| Known as | leucovorin racemate | “leucovorin racemate 200 mg/m2 (or 100 mg/m2 l-LV) IV infusion” NCT00101894 ↗ |
| Known as | Leucovorina | “Drug: Folinic acid/ Leucovorina” NCT07490301 ↗ |
| Known as | Leukovorin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01481272 ↗ |
| Known as | levofolinate | “modified folinic acid [or levofolinate], fluorouracil, and oxaliplatin regimen” PMID 37068504 ↗ Apr 2023 |
| Known as | levofolinic acid | “leucovorin calcium (CF) (or levofolinic acid) orally or IV beginning 36 hours after initiation of MTX infusion” NCT00003728 ↗ |
| Known as | LV | “LV” NCT01212822 ↗ |
| Known as | NSC-119875 | “NSC-119875 CF Leucovorin calcium” NCT00002783 ↗ |
| Known as | NSC-3590 | “5-Fluorouracil, 5-FU, NSC-19893; with Leucovorin calcium, Citrovorum Factor, CF, NSC-3590.” NCT00425152 ↗6“Fluorouracil, 5-FU, NSC-19893; with Leucovorin calcium, CF, NSC-3590.” NCT00002570 ↗ “Leucovorin calcium, Citrovorum Factor, CF, NSC-3590” NCT00002471 ↗ “with Leucovorin calcium, CF, NSC-3590.” NCT00002692 ↗ “Leucovorin calcium, CF, NSC-3590” NCT00002476 ↗ “CF Leucovorin calcium, NSC-3590” NCT00002557 ↗ “CF Leucovorin, NSC-3590” NCT00002691 ↗ |
| Known as | sodium folinate | “Folinic acid 200 mg/m2 over 24 hours day 1, 8, 15, 22, 29, 36 FA will be given as sodium folinate” NCT01123811 ↗ |
| Known as | USEL/Leucovorin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00209742 ↗ |
| Action | Inhibit | “Leucovorin is a prodrug which has to be metabolized to methylenetetrahydrofolate (mTHF) in order to increase inhibition of the target enzyme thymidylate synthase (TS).” NCT02959541 ↗ |
| Modality | Small molecule | “Calcium N-\[p-\[ [ (6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6- pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)” NCT03167177 ↗ |
| Route | Oral | “Patients also take leucovorin calcium orally three times weekly.” NCT00000643 ↗ |